

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ :C07D 471/04, A61K 31/47
C07D 215/44, 401/04, 215/42

A1

(11) International Publication Number:

WO 93/03030

(43) International Publication Date:

18 February 1993 (18.02.93)

(21) International Application Number: PCT/US92/05435

(22) International Filing Date: 1 July 1992 (01.07.92)

(30) Priority data:

740,825

2 August 1991 (02.08.91)

US

(60) Parent Application or Grant

(63) Related by Continuation

US

Filed on

740,825 (CIP)

2 August 1991 (02.08.91)

(71) Applicant (for all designated States except US): PFIZER
INC. [US/US]; 235 East 42nd Street, New York, NY
10017 (US).


(72) Inventors; and

(75) Inventors/Applicants (for US only): MOYER, Mikel, P.
[US/US]; 16 Christopher Lane, Clinton, CT 06413 (US).
McFARLAND, James, W. [US/US]; 24-2 Burr Road,
Lyme, CT 06371 (US).(74) Agents: RICHARDSON, Peter, C. et al.; Pfizer Inc., 235
East 42nd Street, New York, NY 10017 (US).(81) Designated States: CA, FI, JP, US, European patent (AT,
BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL,
SE).

Published

With international search report.

(54) Title: QUINOLINE DERIVATIVES AS IMMUNOSTIMULANTS



(57) Abstract

This invention relates to compounds of formula (I) wherein R¹, R², R³, R⁴, R⁵, R⁶ and R⁷ are as defined. These compounds exhibit activity as immunostimulants.

BEST AVAILABLE COPY

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FI	Finland	MN	Mongolia
AU	Australia	FR	France	MR	Mauritania
BB	Barbados	GA	Gabon	MW	Malawi
BE	Belgium	GB	United Kingdom	NL	Netherlands
BF	Burkina Faso	GN	Guinea	NO	Norway
BG	Bulgaria	GR	Greece	NZ	New Zealand
BJ	Benin	HU	Hungary	PL	Poland
BR	Brazil	IE	Ireland	PT	Portugal
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	RU	Russian Federation
CG	Congo	KP	Democratic People's Republic of Korea	SD	Sudan
CH	Switzerland	KR	Republic of Korea	SE	Sweden
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovak Republic
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CS	Czechoslovakia	LU	Luxembourg	SU	Soviet Union
CZ	Czech Republic	MC	Monaco	TD	Chad
DE	Germany	MG	Madagascar	TG	Togo
DK	Denmark	ML	Mali	UA	Ukraine
ES	Spain			US	United States of America

-1-


5 QUINOLINE DERIVATIVES AS IMMUNOSTIMULANTS

The present invention relates to novel quinoline derivatives that exhibit activity as immunostimulants. By improving a host's immune response, the compounds of this invention increase the host's resistance to infection or
 10 infestation by bacteria, viruses, fungi, etc. They are therefore useful, alone or in combination with anti-infective therapy, in the prophylactic or therapeutic treatment of any infectious disease.

U.S. Patent No. 4,716,168, assigned to Norwich Eaton
 15 Pharmaceuticals, Inc. refers to other quinoline derivatives, more specifically, to imidazo(4,5-f)quinolines, and states that such compounds are useful in enhancing the immune response system of a mammal.

Summary of the Invention

20 The present invention relates to compounds of the formula



wherein R¹ is (C₃-C₁₈) alkyl or phenyl optionally substituted with from one to three substituents independently selected from (C₁-C₆) alkyl, (C₁-C₆) alkoxy, halo, cyano, (C₃-C₈) cycloalkyl-(C₁-C₆)alkoxy wherein the cycloalkyl moiety may be
 35 substituted with from one to three (C₁-C₆)alkyl groups; hydroxyl, benzyloxy, carboxyl, hydroxy-(C₁-C₆) alkyl, pyrrolidino, piperidino, morpholino and -CONHQCOOH wherein Q is (C₁-C₄) alkyl;

R² is hydrogen, (C₁-C₆) alkyl, (C₃-C₇) cycloalkyl, phenyl
 40 or phenyl-(C₁-C₆) alkyl, wherein the phenyl moieties of said phenyl and said phenyl-(C₁-C₆) alkyl may be optionally


-2-

substituted with from one to three substituents independently selected from (C₁-C₆) alkyl, (C₁-C₆)-alkoxy, halo, cyano and benzyloxy;

each of R³ and R⁴ is hydrogen;

5 R^5 is hydrogen, amino, hydroxyl, 5-pyrazolyl, guanidino, hydroxy-(C_1-C_6) alkyl, $-NHC(=NR^8)R^9$, $-NH SO_2 R^{11}$, $-NHCOR^{12}$ or ureido;

or R⁴ and R⁵, together with the carbons to which they are attached, form a group of the formula .



wherein the carbon of group A labelled with an asterisk (*)
20 represents the point of attachment of R^4 to the quinoline
nucleus and the carbon of group A adjacent to it represents
the point of attachment of R^5 to the quinoline nucleus;

R^6 is hydrogen, hydroxyl, amino, guanidino, $-NHC(=NR^8)R^9$, $-NHCOR^{13}$, $-NH\text{SO}_2R^{13}$ or ureido;

25 R⁷ is hydrogen, halo, hydroxyl, amino, -NHC(=NR⁸)R⁹,
-NHSO₂R¹⁴, -NHCOR¹⁴, ureido or guanidino;

R⁸ and R⁹ are independently selected from hydrogen, phenyl and (C₁-C₆)alkyl;

R¹¹, R¹², R¹³ and R¹⁴ are independently selected from (C₁-C₆) alkyl and phenyl optionally substituted with halo, (C₁-C₆)alkyl or (C₁-C₆)alkoxy;

except for 6-amino-4-anilino-2-phenylquinoline
hydrochloride, 6-amino-4-(m-anisidino)-2-phenylquinoline
hydrochloride, 6-amino-4-cyclohexylamino-2-phenylquinoline
35 hydrochloride, 6-amino-4-(m-anisidino)-2-methylquinoline
methanesulfonate, 6-amino-4-(p-toluidino)-2-methylquinoline
methanesulfonate, 9-(p-anisidino)-2-methyl-1H-pyrazolo[3,4-

-3-

f]quinoline hydrochloride, 9-(cyclohexylamino)-1H-pyrazolo[3,4-f]quinoline methanesulfonate, 9-(cyclopentylamino)-1H-pyrazolo[3,4-f]quinoline methane-sulfonate, 4-(phenylamino)-2-phenylquinolin-6-ol
5 hydrobromide; 4-(butylamino)-2-phenylquinolin-6-ol hydrobromide; 4-[(3-methoxyphenyl)amino]-2-methylquinolin-7-ol hydrochloride; 4-[(4-chlorophenyl)amino]-2-methylquinolin-7-ol hydrobromide; 4-(cyclohexylamino)-2-methylquinolin-6-ol hydrochloride; 4-[(3-methoxyphenyl)-
10 amino]quinolin-6,8-diol hydrochloride; and 4-(cyclohexylamino)quinolin-8-ol hydrochloride.

This invention also relates to the pharmaceutically acceptable acid addition salts and cationic salts of compounds of the formula I.

15 Unless otherwise indicated, the term "halo", as used herein, includes fluoro, chloro, bromo and iodo.

Unless otherwise indicated, the term "alkyl", as used herein, may be straight, branched or cyclic, and may include straight and cyclic moieties as well as branched and cyclic
20 moieties.

The compounds of formula I may have chiral centers and therefore may occur in different stereoisomeric configurations. The invention includes all stereoisomers of such compounds of formula I, including mixtures thereof.


25 The present invention also relates to all radiolabelled forms of the compounds of the formula I. Such radiolabelled compounds are useful as research and diagnostic tools in metabolism pharmacokinetic studies and in binding assays in both animals and man.

30 The present invention also relates to a pharmaceutical composition for enhancing or stimulating the immune response of vertebrates, including humans, cattle, swine and poultry, comprising an immune response enhancing or stimulating amount of a compound of the formula I, or a pharmaceutically
35 acceptable salt thereof, and a pharmaceutically acceptable carrier.

-4-

The present invention also relates to a method for enhancing or stimulating the immune response of vertebrates, including humans, cattle, swine and poultry, comprising administering to a vertebrate an immune response enhancing
 5 or stimulating amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof.

Preferred compounds of this invention are compounds of the formula I wherein R^3 , R^6 and R^7 are hydrogen, and R^4 and R^5 , together with the carbons to which they are attached,
 10 form a group of the formula



15

wherein the carbon labelled with an asterisk (*) represents the point of attachment of R^4 to the quinoline nucleus and the adjacent carbon of group A represents the point of
 20 attachment of R^5 to the quinoline nucleus.

Other preferred compounds of this invention are compounds of the formula I wherein R^3 , R^4 , R^6 and R^7 are hydrogen and R^5 is amino, $-NH\text{SO}_2R^{11}$, $-NHCOR^{12}$ or hydroxy.

Specific preferred compounds of this invention are:

25 9-(m-Anisidino)-7-methyl-1H-pyrazolo[3,4-f]quinoline hydrochloride;

9-(p-Cyclohexylmethoxyanilino)-7-methyl-1H-pyrazolo[3,4-f]quinoline;

30 9-(Cyclohexylamino)-7-methyl-1H-pyrazolo[3,4-f]quinoline;

9-(p-Cyclohexylmethoxyanilino)-1H-pyrazolo[3,4-f]quinoline;

6-Amino-4-(p-cyclohexylmethoxyanilino)-2-phenylquinoline;

35 6-Amino-4-(p-chloroanilino)-2-phenylquinoline;

4-(p-Cyclohexylmethoxyanilino)-6-methylsulfonamido-2-phenylquinoline;

-5-

4-Decylamino-2-methylquinolin-6-ol;

4-Tetradecyl-2-methylquinolin-6-ol;

4-(Dodecylamino)quinolin-6-ol;

Other compounds of the invention are:

- 5 9-(p-Butoxyanilino)-7-methyl-1H-pyrazolo[3,4-f]quinoline;
- 9-(p-Chloroanilino)-7-methyl-1H-pyrazolo[3,4-f]quinoline;
- 9-(p-Benzoyloxyanilino)-7-methyl-1H-pyrazolo[3,4-f]quinoline;
- 10 9-(p-Hydroxyanilino)-7-methyl-1H-pyrazolo[3,4-f]quinoline;
- 9-(m-Anisidino)-7-methyl-1H-triazolo[3,4-f]quinoline;
- 9-(m-Anisidino)-1H-pyrazolo[3,4-f]quinoline;
- 15 9-(p-Chloroanilino)-1H-pyrazolo[3,4-f]quinoline;
- 6-Amino-4-(p-butoxyanilino)-2-phenylquinoline;
- 6-Amino-4-(p-anisidino)-2-phenylquinoline;
- 4-(m-Anisidino)-2-methyl-6-(5-pyrazolo)quinoline;
- 4-(p-Cyclohexylmethoxyanilino)-2-methyl-6-(5-pyrazolo)quinoline;
- 20 9-(4-Ethylanilino)-7-methyl-1H-pyrazolo[3,4-f]quinoline;
- 7-Methyl-9-(4-propylanilino)-1H-pyrazolo[3,4-f]quinoline;
- 25 7-Methyl-9-(4-toluidino)-1H-pyrazolo[3,4-f]quinoline;
- 9-Cyclopentylamino-7-methyl-1H-pyrazolo[3,4-f]quinoline;
- 9-(4-Ethoxyanilino)-1H-pyrazolo[3,4-f]quinoline;
- 9-(4-Ethylanilino)-1H-pyrazolo[3,4-f]quinoline;
- 30 9-(4-Propylamino)-1H-pyrazolo[3,4-f]quinoline;
- 9-(4-Butylanilino)-1H-pyrazolo[3,4-f]quinoline;
- 9-(p-Toluidino)-1H-pyrazolo[3,4-f]quinoline;
- 9-(4-Butoxyanilino)-1H-pyrazolo[3,4-f]quinoline;
- 6-Amino-4-(m-anisidino)quinoline;
- 35 6-Amino-4-(p-butoxyanilino)quinoline;
- 6-Amino-4-(3,4-difluoroanilino)-2-phenylquinoline;
- 4-(p-Cyclohexylmethoxyanilino)-2-phenyl-6-

-6-

- ureidoquinoline;
6-Acetamido-4-(p-cyclohexylmethoxyanilino)-2-phenylquinoline;
N-[4-(Cyclohexylmethyloxy)phenyl]-2-methylquinolin-4,8-
5 diamine;
4-(4-Butylphenylamino)-2-methylquinolin-6-ol;
4-(4-Chlorophenylamino)-2-methylquinolin-6-ol;
4-(4-Chlorophenylamino)-2-phenylquinolin-6-ol;
2-Methyl-4-octylaminoquinolin-6-ol Hydrobromide;
10 4-[4-(Cyclohexylmethyloxy)phenylamino]-2-methyl-
quinolin-6-ol;
4-(3-Methoxyphenylamino)-2-methylquinolin-6-ol;
4-Hexylamino-2-methylquinolin-6-ol;
4-Dodecylamino-2-methylquinolin-6-ol;
15 4-[(3-Methoxyphenyl)amino]quinolin-6-ol;
4-[(4-Cyclohexylmethyloxy)phenylamino]quinolin-6-ol;
4-(Cyclohexylamino)quinolin-6-ol;
4-(Decylamino)quinolin-6-ol;
4-(4-Butylphenylamino)-2-methylquinolin-7-ol;
20 4-[4-(Cyclohexylmethyloxy)phenylamino]-2-methyl-
quinolin-7-ol;
4-(Dodecylamino)-2-methylquinolin-7-ol;
4-(Decylamino)-2-methylquinolin-7-ol;
4-(4-Butylphenylamino)quinolin-8-ol;
25 4-[4-(Cyclohexylmethyloxy)phenylamino]quinolin-8-ol;
4-(Dodecylamino)quinolin-8-ol;
4-[4-(Cyclohexylmethyloxy)phenylamino]quinolin-6,8-
diol; and
4-[4-(Cyclohexylmethyloxy)phenylamino]quinolin-6-
30 methanol.
Examples of other compounds of the formula I include:
7-methyl-9-(4-pyrrolidinoanilino)-1H-pyrazolo[3,4-f]-
quinoline hydrochloride;
9-(4-aminohippuroyl)-7-methyl-1H-pyrazolo[3,4-f]-
35 quinoline hydrochloride;
9-(4-carboxyanilino)-7-methyl-1H-pyrazolo[3,4-f]-
quinoline hydrochloride;


-7-

- 9-(m-anisidino)-7-cyclohexyl-1H-pyrazolo[3,4-f]quinoline hydrochloride;
- 4-(m-anisidino)-6-phenylsulfonamidoquinoline hydrochloride;
- 5 4-(m-anisidino)-7-methylsulfonamidoquinoline hydrochloride;
- 4-(m-anisidino)-8-methylsulfonamidoquinoline hydrochloride;
- 4-(p-ethoxyanilino)-6-guanidinoquinoline hydrochloride;
- 10 4-(p-cyclohexylmethoxyanilino)-6-guanidinoquinoline hydrochloride;
- 4-(p-ethoxyanilino)-7-guanidinoquinoline hydrochloride;
- 4-(p-cyclohexylmethoxyanilino)-7-guanidinoquinoline hydrochloride;
- 15 4-(p-ethoxyanilino)-8-guanidinoquinoline hydrochloride;
- 4-(p-cyclohexylmethoxyanilino)-8-guanidinoquinoline hydrochloride;
- 6-acetamidino-4-(m-anisidino)quinoline hydrochloride;
- 7-acetamidino-4-(m-anisidino)quinoline hydrochloride;
- 20 8-acetamidino-4-(m-anisidino)quinoline hydrochloride;
- 7-amino-4-(m-anisidino)quinoline hydrochloride;
- 4-(p-cyclohexylmethoxyanilino)-7-ureidoquinoline hydrochloride;
- 4-(p-cyclohexylmethoxyanilino)-8-ureidoquinoline hydrochloride;
- 25

Detailed Description of the Invention


The reaction scheme below illustrates the synthesis of the compounds of this invention. In the reaction schemes and discussion that follow, except where otherwise stated, formula I and substituents R¹ through R¹⁴ are defined as above.

-8-

SCHEME

-9-


The above reaction scheme illustrates a method of preparing compounds of the formula I. For those compounds of the formula I wherein R^2 is other than hydrogen, an initial condensation reaction is carried out by reacting a substituted amine of the formula II with an appropriately functionalized beta-keto ester of the formula



VI

wherein R^{15} is methyl or ethyl. This reaction is generally carried out in an inert solvent such as ethyl ether, a halogenated hydrocarbon, dimethylformamide (DMF), acetonitrile or a lower alcohol, preferably ethanol, at a temperature from about ambient temperature to about the reflux temperature of the solvent, preferably from about 40°C to about 100°C. It is preferable to remove water as it is formed in the reaction using, for example, molecular sieves, sodium sulfate, magnesium or calcium sulfate (preferably calcium sulfate), and to catalyze the reaction with a small quantity of acid (e.g., hydrochloric acid, sulfuric acid, paratoluenesulfonic acid or phosphoric acid), preferably acetic acid.

For those compounds wherein R^2 is hydrogen, the condensation reaction is carried out by reacting a malonate of the formula VII



VII

-10-

wherein each R^{15} is independently selected from methyl and ethyl, with an amine the formula II in an inert solvent, preferably toluene, at a temperature from about ambient temperature to about the reflux temperature of the solvent, preferable from about 20°C to about 120°C.

The compound of formula III produced in the foregoing reaction may be cyclized by heating it in a high boiling, inert solvent (e.g., xylenes, mesitylene or diphenyl ether), preferably diphenyl ether/biphenyl (Dowtherm, trademark), at a temperature from about 140°C to about 270°C, preferably about 250°C. Where substitution of the aniline of formula II is unsymmetrical, cyclization may yield a compound of the formula IV as a mixture of isomers. These isomers may be separated by a number of purification methods well known to those skilled in the art (e.g., chromatography, crystallization, etc.)

The condensation reaction using a compound of the formula VII and the subsequent cyclization reactions described above produce compounds wherein R^3 is $-COOR^{15}$. These esters can be converted to the corresponding carboxylic acids, and the resulting acids decarboxylated to form the corresponding compounds wherein R^3 is hydrogen. The hydrolysis reaction is typically conducted using an alkali metal hydroxide in water, a lower alcohol, tetrahydrofuran (THF), acetonitrile or an aqueous mixture of these solvents. It is preferably in aqueous sodium hydroxide. Suitable temperatures for this reaction range from about room temperature to about the reflux temperature of the solvent. The reflux temperature is preferred. The decarboxylation is generally carried out by heating the acid in an inert solvent (e.g., quinoline, diphenyl ether or mesitylene), preferably in diphenyl ether/biphenyl (Dowtherm, trademark), at a temperature from about 150°C to about 280°C, preferably about 250°C.

Compounds of the formula IV wherein R^2 is hydrogen are preferably prepared by condensing the appropriate aniline of formula II with 5-(alkoxymethylene)-2,2-dimethyl-1,3-

-11-

dioxane-4,6-dione and then heating the so obtained 5-(anilinomethylene)-2,2-dimethyl-1,3-dioxane-4,6-dione at 200°C to about 270°C according to procedures described in the literature. (See McNab *et al.*, J. Chem. Soc. Perkin Trans. I, 853-868 (1988); Culbertson *et al.*, J. Heterocyclic Chem., 24, 1509-1520 (1987); Matyus *et al.*, Heterocycles, 20, 2225-2228 (1983); Bihlmayer *et al.*, Montash. Chem., 98, 584-578 (1967); and British Patent 1,147,760 (1966) to Sterling Drug Inc.)

- 10 Treatment of a compound of the formula IV with phosphorus pentachloride, phosphorus oxychloride or a mixture of the two yields the corresponding compound of formula V. The reaction temperature may range from about -10°C to about 180°C. Preferably, the compound of formula IV
- 15 is treated with phosphorus oxychloride and DMF at a temperature from about 0°C to about 75°C.

Compounds of the formula V may be converted to the corresponding compounds of formula I by reacting them with the appropriate amine of the formula HNR^1 neat or in an inert

20 solvent such as a lower alcohol, a halogenated hydrocarbon or (DMF), preferably ethanol, at a temperature from about ambient temperature to about 180°C, depending on the reactivity of the particular amine. The preferred solvent is ethanol.

- 25 Compounds of the formula I wherein R^5 , R^6 or R^7 is amino may be prepared by reduction of the corresponding compounds wherein R^5 , R^6 or R^7 , respectively, is nitro using methods well known in the art. (See March, "Advanced Organic Chemistry", pp. 1125-1126, McGraw-Hill Book Company, New
- 30 York, 1977). It is preferable to use hydrogen gas at a pressure of about 1 atmosphere in the presence of palladium on carbon, and to conduct the reaction in a lower alcohol solvent at about room temperature.


Similarly, compounds of the formula I wherein R^5 is

35 $-\text{NHC}(=\text{NR}^8)\text{R}^9$, $-\text{NHSO}_2\text{R}^{11}$, $-\text{NHCOR}^{12}$, guanidino or ureido, or wherein R^6 is $-\text{NHCOR}^{13}$, $-\text{NHC}(=\text{NR}^8)\text{R}^9$, $-\text{NHSO}_2\text{R}^{13}$, guanidino or ureido, or wherein R^7 is $-\text{NHC}(=\text{NR}^8)\text{R}^9$, $-\text{NHSO}_2\text{R}^{14}$, $-\text{NHCOR}^{14}$,

-12-

ureido or guanidino, may be prepared from the corresponding amino compounds using procedures well known to those skilled in the art. (See, for the preparation of amides, March, "Advanced Organic Chemistry", pp. 392-393, McGraw-Hill Book Company, New York, 1977. See, for the preparation of sulfonamides, March, "Advanced Organic Chemistry", pp. 451-452, McGraw-Hill Book Company, New York, 1977. See, for the preparation of amidines, March, "Advanced Organic Chemistry", pp. 823-824 and p. 891, McGraw-Hill Book Company, New York, 1977. See, for the preparation of ureas, March, "Advanced Organic Chemistry", pp. 823, McGraw-Hill Book Company, New York, 1977. See, for the preparation of guanidines, Scott *et al.*, J. Amer. Chem. Soc., 75, 4053 (1953), Bannard, R.A.B. *et al.*, Can. J. Chem., 36, 1541 (1958) and Bodansky, M., J. Amer. Chem. Soc. 86, 4452 (1964).

Compounds of the formula I wherein R⁵, R⁶ or R⁷ is hydroxy or wherein R⁵ and R⁶, or R⁵ and R⁷ are both hydroxy may be prepared by treating the corresponding methoxy compounds with concentrated hydrogen bromide or hydrogen iodide or by heating them with aluminum chloride in an appropriate solvent such as toluene heated at reflux. Alternatively, the corresponding methoxy intermediates can be treated with boron tribromide or boron tribromide-methyl sulfide complex in an appropriate solvent such as methylene chloride or 1,2-dichloroethane, as exemplified below.



The resulting hydroxy compounds can then be reacted with the appropriate amines, as described above, to produce the desired compounds of structure I that are substituted in 5, 6 and/or 7 positions.

-13-

Compounds of the formula I wherein R⁵ is 5-pyrazolyl may be prepared as described in Example 17.

Except where otherwise noted, pressure is not critical in any of the above reactions. Preferred temperatures for the above reactions were stated where known. In general, the preferred temperature for each reaction is the lowest temperature at which product will be formed.

The pharmaceutically acceptable acid addition salts of compounds of the formula I are prepared in a conventional manner by treating a solution or suspension of the free base of formula I with about one chemical equivalent of a pharmaceutically acceptable acid. Conventional concentration and recrystallization techniques are employed in isolating the salts. Examples of pharmaceutically acceptable acids are acetic, lactic, succinic, maleic, tartaric, citric, gluconic, ascorbic, benzoic, methanesulfonic, cinnamic, fumaric, phosphonic, hydrochloric, hydrobromic, hydroiodic, sulfamic and sulfonic acid.

The active compounds of this invention and their pharmaceutically acceptable acid addition salts are useful in stimulating, restoring or enhancing the immune response of a host vertebrate, thus increasing the host's resistance to infection or infestation by bacteria, viruses, fungi, etc. They are therefore useful, alone or in combination with antiinfective therapy, in the prophylactic or therapeutic treatment of any infectious disease.

The activity of the compounds of this invention as immunostimulants may be determined by the following procedure.

Mice (Harlan Sprague Dawley, female) in the control group (i.e., those not receiving drug) and those in the experimental group are infected with E. coli 51A760 (2 x 10⁷ colony forming units) by intraperitoneal injection. (A subtherapeutic dose of gentamicin (0.5 mg/kg) may be optionally administered subcutaneously to mice in both the experimental and the control group 0.5, 4, and 24 hours

-14-

after such injection). Twenty-four hours before the injection with E. coli, the mice in the experimental group are treated subcutaneously with drug dissolved or suspended in pyrogen-free saline. The number of surviving mice in the control and experimental groups 96 hours after such infection is recorded. A compound is considered active if the number of surviving mice in the experimental group is significantly higher than those surviving in the control group.

10 The compounds of this invention may be administered alone, but will generally be administered in admixture with a pharmaceutical carrier selected with regard to the intended route of administration and standard pharmaceutical practice. They can be injected parenterally, for example, 15 intramuscularly, intravenously or subcutaneously. For parenteral administration, they are best used in the form of a sterile aqueous solution which can contain other solutes, for example, enough salt or glucose to make the solution isotonic. In the case of vertebrates other than humans, 20 compounds can be administered intramuscularly or subcutaneously at dosage levels of about 0.1-50 mg/kg/day, advantageously 0.2-10 mg/kg/day given in a single daily dose or up to 3 divided doses.

The compounds of this invention can be administered to 25 humans for the treatment of bacterial diseases by the parenteral route. For intramuscular or intravenous administration, dosage levels are about 0.1-200 mg/kg/day, advantageously 0.5-50 mg/kg/day. While intramuscular administration may consist of a single dose or up to 3 30 divided doses, intravenous administration can consist of a continuous drip. Variations will necessarily occur depending on the weight and condition of the subject being treated and the particular route of administration chosen, as will be known to those skilled in the art.

35 The present invention is illustrated by the following examples. It will be understood, however, that the invention is not limited to the specific details of these

-15-

examples. Melting points are uncorrected. Proton nuclear magnetic resonance spectra (^1H NMR) and ^{13}C nuclear magnetic resonance spectra (^{13}C NMR) were measured for solutions in deuterodimethylsulfoxide (d_6 -DMSO) and peak positions are expressed in parts per million (ppm) downfield from tetramethylsilane (TMS). The peak shapes are denoted as follows: s, singlet; d, doublet, t, triplet; q, quartet; m, multiplet; br, broad; c, complex.

EXAMPLE 1

10 9-(m-Anisidino)-7-methyl-1H-pyrazolo[3,4-f]quinoline hydrochloride

 A. 9-Hydroxy-7-methyl-1H-pyrazolo[3,4-f]quinoline

To a suspension of 6-aminoindazole (40.0 g, 0.30 mol) in absolute ethanol (500 ml) was added ethyl acetoacetate (70.37 g, 54 mol), calcium sulfate (CaSO_4) (20 g) and acetic acid (2 ml). The reaction mixture was heated to reflux and after 24 hours more calcium sulfate (10 g) and ethyl acetoacetate (19 ml) was added and the reflux continued for another 24 hour period. It was necessary to add more CaSO_4 (5 g) and ethyl acetoacetate (10 ml) and to reflux the reaction mixture for an additional 24 hours to complete the conversion of 6-aminoindazole to product. The solid was removed by filtration and the filtrate subjected to rotary evaporation. Ethanol was added and the slurry cooled in a refrigerator. The solid was collected by filtration, washed with hexanes and dried in a vacuum oven to give the cyclization precursor ethyl 3-(indazol-6-ylamino)but-2-enoate as a light brown solid (62.19 g, 84%).

A fraction of this material (30.00 g, 0.12 mol) was added to boiling diphenyl ether/biphenyl, (Dowtherm trademark), (i.e., a mixture of biphenyl and diphenylether) (600 ml) in portions. Upon completion of the addition, the reaction was continued for an additional 6 minutes. On cooling the reaction a precipitate formed which was collected by filtration and washed thoroughly with hexanes to give 9-hydroxy-7-methyl-1H-pyrazolo[3,4-f]quinoline as a tan solid (23 g, 94%).

-16-

¹H NMR: δ 2.40 (s, 3H), 6.10 (s, 1H), 7.22 (d, 1H, J=8), 7.84 (d, 1H, J=8), 8.08 (s, 1H).

B. 9-Chloro-7-methyl-1H-pyrazolo[3,4-f]quinoline

To a suspension of 9-hydroxy-7-methyl-1H-pyrazolo[3,4-f]quinoline (8.00 g, 0.04 mmol) in phosphorus oxychloride (61.6 g, 0.40 mol) was added slowly N,N-dimethylformamide (40 ml). After the addition was complete, the reaction mixture was warmed to 80°C for 1 hour and then allowed to cool to room temperature. The reaction was poured onto ice and dissolved in water (2 L total volume) and neutralized to pH 7 with 20% sodium hydroxide (NaOH). The precipitate which formed upon neutralization was collected by filtration, washed with water and dried under vacuum to give 9-chloro-7-methyl-1H-pyrazolo[3,4-f]quinoline as a white solid (8.07 g, 92%).

¹H NMR: δ 2.66 (s, 3H), 7.61 (d, 1H, J=9), 7.72 (s, 1H), 8.07 (d, 1H, J=9), 8.33 (s, 1H).

C. 9-(m-Anisidino)-7-methyl-1H-pyrazolo[3,4-f]quinoline hydrochloride

To a solution of 9-chloro-7-methyl-1H-pyrazolo[3,4-f]quinoline (1.63 g, 7.5 mmol) in ethanol (60 ml) was added m-anisidine (1.11 g, 9.0 mmol) and the mixture was heated at reflux overnight. The solvent was removed by rotary evaporation and the residue redissolved in methanol and treated with decolorizing carbon. After filtration through diatomaceous earth (CeliteTM), the filtrate was subjected to rotary evaporation and the resulting pale yellow solid recrystallized from methanol/ethyl ether to give 9-(m-anisidino)-7-methyl-1H-pyrazolo[3,4-f]quinoline hydrochloride (2.35 g, 92%) as pale yellow needles.

¹H NMR: δ 2.72 (s, 3H), 3.85 (s, 3H), 7.05 (d, 1H, J=8), 7.12 (s, 1H), 7.14-7.18 (m, 2H), 7.50 (t, 1H, J=8), 7.72 (d, 1H, J=9), 8.34 (d, 1H, J=9), 8.84 (s, 1H).

M.S.: m/e 304 (M⁺, 100).

Analysis: Calc'd for C₁₈H₁₆N₄O•HCl•1.5H₂O: C, 58.78; H, 5.48; N, 15.23%. Found: C, 59.19; H, 5.51; N, 14.96%.

-17-

The title compound of Examples 2-6 were prepared by reaction of 9-chloro-7-methyl-1H-pyrazolo[3,4-f]quinoline with the requisite aniline derivative according to the procedure described in Example 1.

5

EXAMPLE 29-(p-Cyclohexylmethoxyanilino)-7-methyl-1H-pyrazolo[3,4-f]quinoline hydrochloride

¹H NMR: δ 1.1-1.4 (m, 5H), 1.7-2.0 (m, 6H), 2.64 (s, 3H), 3.83 (d, 2H, J=6), 6.86 (s, 1H), 7.10 (d, 2H, J=9),
10 7.45 (d, 2H, J=9), 7.69 (d, 1H, J=9), 8.30 (d, 1H, J=9), 8.83 (s, 1H).

M.S.: m/e 386 (M⁺, 40).

High Resolution Mass Spectrum: Calc'd for C₂₄H₂₆N₄O: 386.2107 Found: 386.2077.

15

EXAMPLE 39-(p-Butoxyanilino)-7-methyl-1H-pyrazolo[3,4-f]quinoline hydrochloride

¹H NMR: δ 0.96 (t, 3H, J=6), 1.46 (m, 2H), 1.72 (m, 2H), 2.66 (s, 3H), 4.04 (t, 2H, J=6), 6.86 (s, 1H), 7.11 (d, 2H, J=9),
20 7.46 (d, 2H, J=9), 7.70 (d, 1H, J=8), 8.30 (d, 1H, J=8), 8.82 (s, 1H).

M.S.: m/e 346 (M⁺, 90).

EXAMPLE 49-(p-Chloroanilino)-7-methyl-1H-pyrazolo[3,4-f]quinoline hydrochloride

¹H NMR: δ 2.68 (s, 3H), 7.06 (s, 1H), 7.62 (m, 4H), 7.68 (d, 1H, J=9), 8.28 (d, 1H, J=9), 8.80 (s, 1H).

M.S.: m/e 309 (M⁺, 100).

Analysis: Calc'd for C₁₇H₁₃N₄Cl•HCl•H₂O: C, 56.21; H, 4.44; N, 15.42%. Found: C, 56.21; H, 4.40; N, 15.24%.

30

-18-

EXAMPLE 59-(p-Benzylloxylanilino)-7-methyl-1H-pyrazolo[3,4-f]quinoline hydrochloride

¹H NMR: δ 2.64 (s, 3H), 5.18 (s, 2H), 6.86 (s, 1H), 7.19
5 (d, 2H, J=8), 7.3-7.5 (m, 7H), 7.65 (d, 1H, J=10), 8.28 (d,
1H, J=10), 8.80 (s, 1H).

M.S.: m/e 380 (M⁺, 25).

Analysis (free base): Calc'd for C₂₄H₂₀N₄O•0.5H₂O: C,
74.02; H, 5.44; N, 14.39%. Found: C, 74.32; H, 5.08;
10 14.26%.

EXAMPLE 69-(p-Hydroxyvanilino)-7-methyl-1H-pyrazolo[3,4-f]quinoline hydrochloride

¹H NMR: δ 2.66 (s, 3H), 6.84 (s, 1H), 6.96 (d, 2H, J=8),
15 7.34 (d, 2H, J=8), 7.66 (d, 1H, J=10), 8.30 (d, 1H, J=10),
8.82 (s, 1H).

M.S.: m/e 290 (M⁺, 100).

Analysis: Calc'd for C₁₇H₁₄N₄O•HCl: C, 62.48; H, 4.63; N,
17.14%. Found: C, 61.91; H, 4.43; N, 16.93%.

EXAMPLE 79-(Cyclohexylamino)-7-methyl-1H-pyrazolo[3,4-f]quinoline hydrochloride

9-Chloro-7-methyl-1H-pyrazolo[3,4-f]quinoline (0.44 g,
2.0 mmol) and cyclohexylamine (0.79 g, 8.0 mmol) were placed
25 in a sealable reaction vessel which was flushed with
nitrogen and then sealed. The reaction was placed in a
175°C bath and heated overnight. The excess cyclohexylamine
was removed by rotary evaporation and the residue dissolved
in methanol and treated with decolorizing carbon. After
30 filtration through diatomaceous earth (CeliteTM), the
methanol was removed by rotary evaporation and the residue
partitioned between ethyl acetate and aqueous potassium
hydroxide (KOH). The organic layer was washed with water
and dried over sodium sulfate (Na₂SO₄), and the solvent was
35 removed by rotary evaporation to give a white solid. The
solid was washed with ether giving 9-(cyclohexylamino)-7-
methyl-1H-pyrazolo[3,4-f]quinoline as white needles (0.38 g,

-19-

68%). The free base was converted to the corresponding hydrochloride salt by treatment with anhydrous hydrogen chloride (HCl)/ether.

¹H NMR: δ 1.3 - 2.2 (m, 10H), 2.74 (s, 3H), 4.0 (br s, 1H), 7.12 (s, 1H), 7.64 (d, 1H, J=8), 8.26 (d, 1H, J=8), 8.80 (s, 1H), 9.41 (d, 1H, J=6).

M.S.: m/e 280(M⁺, 55).

Analysis: Calc'd for C₁₇H₂₀N₄•HCl: C, 64.45; H, 6.68; N, 17.68%. Found: C, 63.98; H, 6.46; N, 17.43%.

10

EXAMPLE 8

9-(m-Anisidino)-7-methyl-1H-triazolo[3,4-f]quinoline hydrochloride

The title compound was prepared by the method described in Example 1 with the modification that 5-aminobenzotriazole was used as the starting material instead of 6-aminoindazole.

¹H NMR: δ 2.76 (s, 3H), 4.85 (s, 3H), 7.00 (d, 1H, J=8), 7.20 (apparent s, 3H), 7.50 (t, 1H, J=8), 8.19 (d, 1H, J=9), 8.44 (d, 1H, J=9).

20

High resolution Mass Spectrum: Calc'd for C₁₇H₁₅N₅O: 305.1277. Found: 305.1278.

EXAMPLE 9

9-(m-Anisidino)-1H-pyrazolo[3,4-f]quinoline hydrochloride

A. Ethyl 3-N-(6-indazolyl)amino-2-ethoxycarbonyl-2-propenoate

6-Aminoindazole (10.00 g, 75 mmol) was suspended in toluene (150 ml) to which diethyl ethoxymethylenemalonate (19.45 g, 90 mmol) was then added and the reaction mixture was heated to reflux. After 3 hours the heat was removed and the reaction mixture was stirred at room temperature overnight. The solvent was removed by rotary evaporation and the residue triturated with hexanes. The tan solid was collected by filtration, washed with hexanes and air dried to give the expected product ethyl 3-N-(6-indazolyl)amino-2-ethoxycarbonyl-2-propenoate (19.26 g, 85%).

-20-

¹H NMR: δ 1.2 (overlapping t, 6H), 4.15 (overlapping q, 4H), 7.08 (d, 1H, J=6), 7.42 (s, 1H), 7.70 (d, 1H, J=6), 7.98 (s, 1H), 8.42 (overlapping s, 2H).

B. 8-Carboxy-9-hydroxy-1H-pyrazolo[3,4-f]quinoline

5 To boiling diphenyl ether/biphenyl, (Dowtherm, trademark), (320 ml) was added ethyl 3-N-(6-indazolyl)amino-2-ethoxycarbonyl-2-propenoate (17.26 g, 57 mmol) portionwise. After the addition was complete the reaction was continued for an additional 15 minutes and then allowed
10 to cool to room temperature. The precipitate which formed upon cooling was collected by filtration and washed thoroughly with hexanes to give 8-carboethoxy-9-hydroxy-1H-pyrazolo[3,4-f]quinoline as a light brown powder (13.31 g, 91%).

15 A mixture of 8-carboethoxy-9-hydroxy-1H-pyrazolo[3,4-f]quinoline (12.31 g, 47.8 mmol) and 10% aqueous sodium hydroxide (96 ml) was refluxed for 8 hours, at which time the dark-colored solution was treated with decolorizing carbon and filtered through diatomaceous earth (Celite™).
20 The filtrate was neutralized with 6M HCl and the resulting precipitate isolated by filtration. The light brown solid was air dried to give 8-carboxy-9-hydroxy-1H-pyrazolo[3,4-f]quinoline (10.08 g, 92%).

¹H NMR: δ 7.48 (d, 1H, J=8), 8.19 (d, 1H, J=8), 8.26 (s, 25 1H), 8.90 (s, 1H).

C. 9-Hydroxy-1H-pyrazolo[3,4-f]quinoline

A mixture of 8-carboxy-9-hydroxy-1H-pyrazolo[3,4-f]quinoline (5.00 g, 21.8 mmol) and quinaldine (50 ml) were refluxed for 20 hours. After cooling, the precipitate was
30 collected by filtration and washed thoroughly with ether to give 9-hydroxy-1H-pyrazolo[3,4-f]quinoline (2.97 g, 74%).

¹H NMR: δ 6.24 (d, 1H, J=7); 7.24 (d, 1H, J=9), 7.96 (m, 2H), 8.10 (s, 1H).

D. 9-Chloro-1H-pyrazolo[3,4-f]quinoline

35 A mixture of 9-hydroxy-1H-pyrazolo[3,4-f]quinoline (2.97 g, 16.0 mmol) and phosphorus oxychloride (24.58 g, 160 mmol) at 0°C was treated with dimethylformamide (DMF) (15.4

-21-

ml) dropwise. After addition was complete, the viscous reaction mixture was allowed to warm to room temperature and stirred overnight. The mixture was then poured onto ice and the resulting dark brown solution was treated with
5 decolorizing carbon and filtered, and the brown filtrate neutralized with 10M NaOH. The light brown solid which resulted was collected by filtration and air dried giving 9-chloro-1H-pyrazolo[3,4-f]quinoline (1.73 g, 53%).

¹H NMR: δ 7.65 (d, 1H, J=9), 7.76 (d, 1H, J=5), 8.08 (d,
10 1H, J=9), 8.34 (s, 1H), 8.78 (d, 1H, J=5).

E. 9-(m-Anisidino)-1H-pyrazolo[3,4-f]quinoline hydrochloride

To a suspension of 9-chloro-1H-pyrazolo[3,4-f]quinoline (1.10 g, 5.4 mmol) in absolute ethanol (50 ml) was added m-
15 anisidine (0.79 ml, 7.1 mmol) and the reaction mixture heated at reflux for 48 hours. The solvent was removed by rotary evaporation and the residue was dissolved in boiling methanol, treated with decolorizing carbon and filtered to give a light yellow solution. The solvent was removed by
20 rotary evaporation and the residue was recrystallized from methanol/ether to give 9-(m-anisidino)-1H-pyrazolo[3,4-f]quinoline hydrochloride (1.04 g, 59%) as off-white crystals.

¹H NMR: δ 3.86 (s, 3H), 6.98 (d, 1H, J=6), 7.16 (m, 2H),
25 7.22 (d, 1H, J=6), 7.48 (t, 1H, J=6), 7.68 (d, 1H, J=9), 8.30 (d, 1H, J=9), 8.50 (d, 1H, J=6), 8.84 (s, 1H).

M.S.: m/e 290(M⁺, 100).

Analysis (mesylate salt): Calc'd for C₁₄H₁₄N₄O•CH₃SO₃H: C, 55.55; H, 4.57; N, 14.16%. Found: C, 55.95; H, 4.70; N,
30 14.50%.

The title compound of Examples 10 and 11 were prepared by reaction of 9-chloro-1H-pyrazolo[3,4-f]quinoline with the requisite aniline derivative according to the procedure described in Example 9.

-22-

EXAMPLE 109-(p-Cyclohexylmethoxyanilino)-1H-pyrazolo[3,4-f]quinoline hydrochloride

¹H NMR: δ 0.9 - 1.3 (m, 5H), 1.6 - 1.9 (m, 6H), 4.82 (d, 2H, J=6), 6.94 (br s, 1H), 7.08 (d, 2H, J=7), 7.44 (d, 2H, J=7), 7.68 (br s, 1H), 8.30 (d, 1H, J=8), 8.46 (br s, 1H), 8.82 (br s, 1H).

M.S.: m/e 371 (M⁺, 30).

EXAMPLE 11

10 9-(p-Chloroanilino)-1H-pyrazolo[3,4-f]quinoline hydrochloride

¹H NMR: δ 7.18 (d, 1H, J=7), 7.6 - 7.7 (m, 5H), 8.37 (d, 1H, J=9), 8.54 (d, 1H, J=7), 8.87 (s, 1H).

M.S.: m/e 294 (M⁺, 100).

15

EXAMPLE 12

6-Amino-4-(p-butoxyanilino)-2-phenylquinoline hydrochloride

A. 4-Chloro-6-nitro-2-phenylquinoline

4-Hydroxy-6-nitro-2-phenylquinoline (10.00 g, 38 mmol) was suspended in phosphorus oxychloride (POCl₃) (57.58 g, 380 mmol) at 0°C. Dimethylformamide (DMF) (45 ml) was added dropwise and the resulting mixture heated at 70°C for 5 hours. The reaction was cooled and then poured onto ice. The pH was adjusted to 6 with aqueous sodium hydroxide and the precipitate collected by vacuum filtration and dried in a vacuum oven to give 4-chloro-6-nitro-2-phenylquinoline (10.95 g, 102%) as a yellow powder.

M.P.: 166-167°C.

¹H NMR: δ 7.5 - 7.6 (m, 3H), 8.3 - 8.4 (m, 3H), 8.52 (s, 1H), 8.61 (dd, 1H, J=9, 3), 9.10 (d, 1H, J=3).

B. 4-(p-Butoxyanilino)-6-nitro-2-phenylquinoline

To a suspension of 4-chloro-6-nitro-2-phenylquinoline (0.57 g, 2.0 mmol) in absolute ethanol (25 ml) was added 4-butoxyaniline (0.40 g, 2.4 mmol), and the mixture was heated at reflux for 4 hours. The solvent was removed by rotary evaporation and the residue was redissolved in methanol, treated with decolorizing carbon and filtered through

-23-

diatomaceous earth (Celite™). The solvent was removed by rotary evaporation. The residue was recrystallized from methanol/ether to give 4-(p-butoxy)-6-nitro-2-phenylquinoline (0.61 g, 69%).

5 ¹H NMR: δ 1.00 (t, 3H, J=6), 1.5 (m, 2H), 1.75 (m, 2H), 4.08 (t, 2H, J=6), 7.00 (s, 1H), 7.18 (d, 2H, J=9), 7.50 (d, 2H, J=9), 7.63 (m, 3H), 7.96 (d, 2H, J=6), 8.54 (d, 1H, J=8), 8.76 (d, 1H, J=8), 9.84 (s, 1H).

C. 6-Amino-4-(p-butoxyanilino)-2-phenylquinoline
10 hydrochloride

To a suspension of 4-(p-butoxy)-6-nitro-2-phenylquinoline (0.42 g, 0.94 mmol) in methanol (25 ml) was added ammonium formate (0.59 g, 9.4 mmol) and, finally, 10% palladium on carbon (Pd/C) (50 mg), and the mixture heated
15 at reflux for 1.5 hours. The reaction was filtered warm through diatomaceous earth (Celite™) and the solvent was removed by rotary evaporation. The remaining solid was washed thoroughly with water and then recrystallized from methanol/ether. The resulting yellow crystals (0.16 g, 40%)
20 were dissolved in methanol (10 ml) and treated with HCl in ether (1M, 8 ml). The solvent was removed and the residue recrystallized twice from methanol/ether to give 6-amino-4-(p-butoxyanilino)-2-phenylquinoline hydrochloride (0.08 g, 48%) as a yellow solid.

25 ¹H NMR: δ 1.00 (t, 3H, J=6), 1.48 (m, 2H), 1.76 (m, 2H), 4.06 (t, 2H, J=5), 6.76 (s, 1H), 7.12 (d, 2H, J=9), 7.44 (d, 2H, J=9), 7.52 (d, 1H, J=6), 7.6 - 7.7 (m, 4H), 7.84 (d, 2H, J=6), 8.16 (d, 1H, J=9).

M.S.: m/e 383 (M⁺, 70).

30 Analysis: Calc'd for C₂₅H₂₅N₃O•2HCl•H₂O: C, 63.29; H, 6.16; N, 8.86%. Found: C, 62.91; H, 6.36; N, 8.63%.

The title compounds of Examples 13-15 were prepared by reaction of 4-chloro-6-nitro-2-phenylquinoline with the requisite aniline derivative according to the procedure
35 described in Example 12.

-24-

EXAMPLE 136-Amino-4-(p-cyclohexylmethoxyanilino)-2-phenylquinoline hydrochloride

¹H NMR: δ 1.1 - 1.2 (m, 5H), 1.6 - 1.8 (m, 6H), 3.81 (d, 5 2H, J=6), 6.70 (s, 1H), 7.07 (d, 2H, J=9), 7.4 - 7.5 (m, 3H), 7.5 - 7.6 (m, 4H), 7.78 (d, 2H, J=8), 8.07 (d, 1H, J=9), 10.31 (s, 1H).

M.S.: m/e 423 (M⁺, 60).

Analysis: Calc'd for C₂₈H₂₉N₃O•2HCl•0.5H₂O: C, 66.53; H, 10 6.38; N, 8.31%. Found: C, 66.54; H, 5.93; N, 8.0%.

EXAMPLE 146-Amino-4-(p-chloroanilino)-2-phenylquinoline hydrochloride

¹H NMR: δ 6.94 (s, 1H) 7.5 - 7.6 (m, 9H), 7.86 (d, 2H, 15 J=6), 8.14 (d, 1H, J=9), 10.44 (s, 1H).

M.S.: m/e 345 (M⁺, 100).

Analysis: Calc'd for C₂₁H₁₆N₃Cl•2H₂O•1.5HCl: C, 57.32; H, 4.49; N, 9.40%. Found: C, 57.78; H, 4.96; N, 9.63%.

EXAMPLE 156-Amino-4-(p-anisidino)-2-phenylquinoline hydrochloride

¹H NMR: δ 3.80 (s, 3H), 7.08 (d, 2H, J=8), 7.43 (d, 2H, J=8), 7.5 - 7.8 (m, 7H), 8.13 (d, 1H, J=9), 10.42 (s, 1H).

M.S.: m/e 341 (M⁺, 100).

Analysis: Calc'd for C₂₂H₁₉N₃O•2HCl•1.5H₂O: C, 59.87; H, 25 5.48; N, 9.08%. Found: C, 59.66; H, 5.44; N, 9.52%.

EXAMPLE 164-(p-Cyclohexylmethoxyanilino)-6-methylsulfonamido-2-phenylquinoline hydrochloride

To a suspension of 6-amino-4-(p-cyclohexylmethoxyanilino)-2-phenylquinoline hydrochloride (0.21 g, 0.5 mmol) in anhydrous THF (10 ml) at 0°C was added methanesulfonyl chloride (69 mg, 0.6 mmol) followed by addition of triethylamine (61 mg, 0.6 mmol). The reaction mixture was allowed to warm slowly to room temperature and 35 stirred overnight. The solvent was removed by rotary evaporation and the residue partitioned between ethyl acetate (EtOAc) and 1M hydrochloric acid. The layers were

-25-

separated, the organic layer was washed with saturated sodium bicarbonate and dried (Na_2SO_4) and the solvent was removed by rotary evaporation. The crude material was dissolved in warm methanol and treated with 1M HCl in ether.

- 5 After 2 hours at room temperature, the solvent was removed by rotary evaporation and the residue recrystallized from methanol/ether to give 4-(p-cyclohexylmethoxyanilino)-6-methylsulfonamido-2-phenylquinoline hydrochloride (38%) as a pale yellow solid.

10 ^1H NMR: δ 0.9 - 1.3 (m, 5H), 1.6 - 1.8 (m, 6H), 3.24 (s, 3H), 3.82 (d, 2H, J=6), 6.78 (s, 1H), 7.09 (d, 2H, J=9), 7.44 (d, 2H, J=9), 7.6 (m, 3H), 7.83 (m, 3H), 8.34 (m, 2H).
M.S.: m/e 502(M^+ , 10).

EXAMPLE 17

- 15 4-(m-Anisidino)-2-methyl-6-(5-pyrazolo)quinoline hydrochloride

A. 4-Nitrobenzoylacetalddehyde

- To a solution of 4-nitroacetophenone (8.26 g, 50 mmol) in anhydrous tetrahydrofuran (THF) at 0°C was slowly added
20 sodium ethoxide in ethanol (prepared from 1.27 g (55 mmol) sodium in 26 ml ethanol) followed by addition of ethyl formate (5.56 g, 75 mmol). The reaction was allowed to slowly warm to room temperature and stir overnight. The reaction was diluted with water (800 ml) and washed with
25 ether. The aqueous layer was acidified (pH 1-2) with concentrated hydrochloric acid (HCl) and the mixture extracted with ethyl acetate. The combined organic layers were dried (Na_2SO_4) and the solvent was removed by rotary evaporation to give 4-nitrobenzoylacetalddehyde (2.69 g, 28%)
30 as an orange solid.

^1H NMR (CDCl_3): δ 6.24 (d, 1H, J=3), 8.02 (d, 2H, J=9), 8.28 (d, 2H, J=9), 8.44 (d, 1H, J=3).

B. 4-(5-Pyrazoyl)nitrobenzene

- To a suspension of 4-nitrobenzoylacetalddehyde (2.75 g, 14.2 mmol) in methanol (100 ml) at 0°C was added hydrazine
35 hydrate (0.50 g, 15.7 mmol). The resulting burgundy solution was stirred at 0°C for 2.5 hours, at which time the

-26-

solvent was removed by rotary evaporation and the residue was partitioned between water and ethyl acetate. The aqueous layer was extracted with more ethyl acetate and the combined organics were then washed with saturated sodium chloride (NaCl) and dried (Na_2SO_4), and the solvent was removed by rotary evaporation to give 4-(5-pyrazoyl)nitrobenzene (2.32 g, 86%) as an orange solid.

^1H NMR: δ 6.90 (s, 1H), 7.84 (s, 1H), 8.04 (d, 2H, $J=9$), 8.22 (d, 2H, $J=9$).

10 C. 4-Hydroxy-2-methyl-6-(5-pyrazolyl)quinoline

To a suspension of 4-(5-pyrazoyl)nitrobenzene (1.25 g, 6.6 mmol) in methanol (60 ml) was added 10% Pd/C (0.13 g) and the mixture shaken under hydrogen (45 psi) for 2 hours. The reaction was filtered through diatomaceous earth (CeliteTM) and the solvent was removed by rotary evaporation to give 4-(5-pyrazoyl)aniline as a brown oil which was used directly in the next reaction.

To a solution of 4-(5-pyrazoyl)aniline (1.05 g, 6.6 mmol) in absolute ethanol (20 ml) was added ethyl acetoacetate (1.72 g, 13.2 mmol), calcium sulfate (2.0 g) and a few drops of acetic acid, and the mixture was heated at reflux for 48 hours, with more calcium sulfate (2.0 g) and ethyl acetoacetate (0.85 g) added after 12 and 36 hours. The reaction was then cooled to room temperature, filtered, and the solvent was removed by rotary evaporation. The residue was triturated with several portions of methanol, the methanol fractions were combined and the solvent was removed by rotary evaporation. The residue was chromatographed (silica gel, 20% ethyl acetate (EtOAc) in methylene chloride (CH_2Cl_2) to 5% methanol (CH_3OH) in EtOAc) to give the condensation product as a yellow oil (0.11 g, 7%). This was cyclized by adding it portionwise to boiling diphenyl ether/biphenyl, (Dowtherm, trademark), (10 ml). After the addition was complete, the reaction was continued for an additional 10 minutes and then allowed to cool to room temperature. The precipitate which formed was collected by filtration, washed well with hexanes and dried

-27-

under vacuum to give 4-hydroxy-2-methyl-6-(5-pyrazoyl)quinoline (63%) as a brown solid.

¹H NMR: δ 2.32 (s, 3H), 5.90 (s, 1H), 6.72 (s, 1H), 7.50 (d, 1H, J=7), 7.78 (s, 1H), 8.06 (d, 1H, J=7), 8.38 (s, 1H).

5 M.S.: m/e 225 (M⁺, 100).

D. 4-Chloro-2-methyl-6-(5-pyrazoyl)quinoline

To a suspension of 4-hydroxy-2-methyl-6-(5-pyrazoyl)quinoline (0.13 g, 0.55 mmol) in phosphorus oxychloride (0.85 g, 5.5 mmol) cooled in a water bath was
10 added DMF (5 ml) dropwise and the reaction mixture was stirred at room temperature overnight. The reaction mixture was poured onto ice and the solution neutralized with 10N NaOH. The precipitate which formed was filtered, washed with water and dried under vacuum to give 4-chloro-2-methyl-
15 6-(5-pyrazoyl)quinoline (0.12 g, 86%) as light brown solid.

¹H NMR: δ 2.66 (s, 3H), 6.86 (s, 1H), 7.70 (s, 1H), 7.84 (s, 1H), 8.00 (d, 1H, J=8), 8.28 (d, 1H, J=8), 8.50 (s, 1H).

E. 4-(m-Anisidino)-2-methyl-6-(5-pyrazoyl)quinoline hydrochloride

20 To a solution of 4-chloro-2-methyl-6-(5-pyrazoyl)quinoline (0.10 g, 0.41 mmol) in absolute ethanol (7.5 ml) was added m-anisidine (61 mg, 0.49 mmol) and the reaction was refluxed overnight. The solvent was removed by rotary evaporation. The residue was redissolved in
25 methanol, treated with decolorizing carbon and filtered through diatomaceous earth (CeliteTM). The solvent was then removed by rotary evaporation. The crude product was recrystallized from methanol/ether to give 4-(m-anisidino)-2-methyl-6-(5-pyrazoyl)quinoline hydrochloride (92 mg, 61%)
30 as yellow needles.

¹H NMR: δ 2.60 (s, 3H), 3.81 (s, 3H), 6.74 (s, 1H), 6.98 (d, 1H, J=8), 7.05 (m, 3H), 7.47 (t, 1H, J=8), 7.86 (s, 1H), 8.05 (d, 1H, J=8), 8.46 (d, 1H, J=8), 9.16 (s, 1H).

M.S.: m/e 330 (M⁺, 100).

35 Analysis: Calc'd for C₂₀H₁₈N₄O•HCl•0.25H₂O: C, 64.69; H, 5.29; N, 15.09%. Found: C, 64.58; H, 5.01; N, 15.10%.

-28-

EXAMPLE 184-(p-Cyclohexylmethoxyanilino)-2-methyl-6-(5-pyrazolo)quinoline hydrochloride

4-Chloro-2-methyl-6-(5-pyrazoyl)quinoline was treated
5 with p-cyclohexylmethoxyaniline using the procedure
described in Example 17 to give 4-(p-
cyclohexylmethoxyanilino)-2-methyl-6-(5-pyrazolo)quinoline
hydrochloride.

¹H NMR: δ 1.0 - 1.3 (m, 5H), 1.6 - 1.9 (m, 6H), 2.48 (s,
10 3H), 3.84 (d, 2H, J=6), 6.52 (s, 1H), 7.02 (s, 1H), 7.08 (d,
2H, J=9), 7.36 (d, 2H, J=9), 7.86 (br s, 1H), 7.98 (d, 1H,
J=7), 8.42 (d, 1H, J=7), 9.10 (s, 1H).

M.S.: m/e 412 (M⁺, 15).

High Resolution Mass Spectrum: Calc'd for C₂₀H₁₈N₄O:
15 412.2263. Found: 412.2243.

The following compounds were prepared by a procedure
similar to that of Example 6.

EXAMPLE 199-(4-Ethylanilino)-7-methyl-1H-pyrazolo[3,4-f]quinoline
20 mesylate

¹H NMR: δ 1.24 (t, 3H, J=7), 2.6 - 2.7 (m, 5H), 7.04 (s,
1H), 7.42 (d, 2H, J=8), 7.48 (d, 2H, J=8), 7.53 (d, 1H,
J=9), 8.34 (d, 1H, J=9), 8.86 (s, 1H).

M.S.: m/e 302 (M⁺, 95).

25 Analysis: Calc'd for C₁₉H₁₈N₄•CH₃SO₃H•0.75H₂O: C, 58.31; H,
5.75; N, 13.60%. Found: C, 58.30; H, 5.37; N, 16.21%.

EXAMPLE 207-Methyl-9-(4-propylanilino)-1H-pyrazolo[3,4-
f]quinoline hydrochloride

30 ¹H NMR: δ 0.93 (t, 3H, J=7), 1.64 (m, 2H), 2.53 (m, 5H),
7.02 (s, 1H), 7.39 (d, 2H, J=8), 7.47 (d, 2H, J=8), 7.70 (d,
1H, J=9), 8.31 (d, 1H, J=9), 8.83 (s, 1H).

M.S.: m/e 316 (M⁺, 70).

Analysis: Calc'd for C₂₀H₂₀N₄•HCl•H₂O: C, 64.77; H, 6.25;
35 N, 15.11%. Found: C, 64.43; H, 6.03; N, 14.89%.

-29-

EXAMPLE 217-Methyl-9-(4-toluidino)-1H-pyrazolo[3,4-f]quinoline hydrochloride

¹H NMR: δ 2.42 (s, 3H), 2.70 (s, 3H), 7.01 (s, 1H), 7.41 (d, 2H, J=8), 7.44 (d, 2H, J=8), 7.72 (d, 1H, J=9), 8.34 (d, 1H, J=9), 8.86 (s, 1H).

M.S.: m/e 288 (M⁺, 100).

Analysis: Calc'd for C₁₈H₁₆N₄•HCl•H₂O: C, 63.06; H, 5.59; N, 16.34%. Found: C, 62.90; H, 5.37; N, 16.21%.

EXAMPLE 229-Cyclopentylamino-7-methyl-1H-pyrazolo[3,4-f]quinoline mesylate

The title compound was prepared as described for Example 7 except that cyclopentylamine was used instead of cyclohexylamine.

¹H NMR: δ 2.6 - 2.8 (m, 6H), 2.2 (m, 2H), 2.32 (s, 3H), 2.68 (s, 3H), 4.34 (m, 1H), 7.04 (s, 1H), 7.44 (d, 1H, J=9), 8.24 (d, 1H, J=9), 8.78 (s, 1H).

M.S.: m/e 266 (M⁺, 95).

Analysis: Calc'd for C₁₆H₁₈N₄•CH₃SO₃H•0.25H₂O: C, 55.66; H, 6.18; N, 15.27%. Found: C, 55.53; H, 5.96; N, 15.20%.

The title compounds of Examples 23-28 were prepared by a procedure similar to that described in Example 1.

EXAMPLE 239-(4-Ethoxyanilino)-1H-pyrazolo[3,4-f]quinoline mesylate

¹H NMR: δ 1.38 (t, 3H, J=6), 2.32 (s, 3H), 4.12 (q, 2H, J=6), 7.00 (d, 1H, J=6), 7.14 (d, 2H, J=8), 7.50 (d, 2H, J=8), 7.58 (d, 1H, J=9), 8.36 (d, 1H, J=9), 8.50 (d, 1H, J=6), 8.88 (s, 1H).

M.S.: m/e 304 (M⁺, 95).

EXAMPLE 249-(4-Ethylanilino)-1H-pyrazolo[3,4-f]quinoline mesylate

¹H NMR: δ 1.24 (t, 3H, J=7), 2.34 (s, 3H), 2.70 (q, 2H, J=7), 7.14 (d, 1H, J=7), 7.42 (d, 2H, J=7), 7.48 (d, 2H, J=7), 7.56 (d, 1H, J=9), 8.36 (d, 1H, J=9), 8.50 (d, 1H, J=6), 8.88 (s, 1H).

-30-

M.S.: m/e 288 (M^+ , 95).

Analysis: Calc'd for $C_{18}H_{16}N_4 \cdot CH_3SO_3H \cdot 1.25H_2O$: C, 56.08; H, 5.57; N, 13.77%. Found: C, 55.72; H, 4.89; N, 13.57%.

EXAMPLE 25

5 9-(4-Propylamino)-1H-pyrazolo[3,4-f]quinoline mesylate

1H NMR: δ 0.94 (t, 3H, J=7), 1.62 (m, 2H), 2.36 (s, 3H), 2.64 (t, 2H, J=7), 7.12 (d, 1H, J=8), 7.40 (d, 2H, J=6), 7.48 (d, 2H, J=6), 7.56 (d, 1H, J=9), 8.36 (d, 1H, J=9), 8.50 (br d, 1H), 8.88 (s, 1H).

10 M.S.: m/e 302 (M^+ , 80).

Analysis: Calc'd for $C_{19}H_{18}N_4 \cdot CH_3SO_3H \cdot 0.5H_2O$: C, 58.95; H, 5.69; N, 13.75%. Found: C, 59.15; H, 5.32; N, 13.63%.

EXAMPLE 26

15 9-(4-Butylanilino)-1H-pyrazolo[3,4-f]quinoline mesylate

1H NMR: δ 0.96 (t, 3H, J=6), 1.35 (m, 2H), 1.62 (m, 2H), 2.36 (s, 3H), 2.68 (t, 2H, J=6), 7.16 (d, 1H, J=7), 7.44 (d, 2H, J=7), 7.50 (d, 2H, J=7), 7.60 (d, 1H, J=9), 8.40 (d, 1H, J=9), 8.54 (br d, 1H, J=7), 8.92 (s, 1H).

M.S.: m/e 316 (M^+ , 70).

20

EXAMPLE 27

9-(p-Toluidino)-1H-pyrazolo[3,4-f]quinoline hydrochloride

1H NMR: δ 2.40 (s, 3H), 7.08 (d, 2H, J=7), 7.38 (d, 2H, J=7), 7.46 (d, 2H, J=7), 7.70 (d, 1H, J=9), 8.34 (d, 1H, J=9), 8.48 (d, 1H, J=7), 8.86 (s, 1H).

25

M.S.: m/e 274 (M^+ , 100).

Analysis: Calc'd for $C_{17}H_{14}N_4 \cdot CH_3SO_3H \cdot 1.25H_2O$: C, 55.02; H, 5.26; N, 14.26%. Found: C, 55.15; H, 5.01; N, 14.13%.

EXAMPLE 28

30 9-(4-Butoxyanilino)-1H-pyrazolo[3,4-f]quinoline hydrochloride

1H NMR: δ 0.94 (t, 3H, J=6), 1.42 (m, 2H), 1.70 (m, 2H), 4.02 (t, 2H, J=5), 6.94 (s, 1H, J=7), 7.10 (d, 1H, J=8), 7.44 (d, 2H, J=8), 7.66 (d, 1H, J=9), 8.32 (d, 1H, J=9), 8.44 (d, 1H, J=7), 8.84 (s, 1H).

35

M.S.: m/e 332 (M^+ , 100).

-31-

EXAMPLE 296-Amino-4-(m-anisidino)quinoline hydrochloride

The title compound was prepared from the corresponding 6-nitro compound by catalytic reduction of the nitro group followed by treatment with HCl in ether. The 6-nitro-4-(m-anisidino)quinoline compound was prepared in an analogous fashion to Example 9 with the modification that 4-nitroaniline was used as the starting material instead of 6-aminoindazole.

¹H NMR: δ 3.79 (s, 3H), 6.78 (d, 2H, J=7), 6.9 - 7.0 (m, 3H), 7.3 - 7.5 (m, 2H), 7.70 (s, 1H), 7.92 (d, 1H, J=9).

M.S.: m/e 265 (M⁺, 100).

EXAMPLE 306-Amino-4-(p-butoxyanilino)quinoline hydrochloride

The title compound was prepared from the corresponding 6-nitro compound by catalytic reduction of the nitro group followed by treatment with HCl in ether. The 6-nitro-4-(p-butoxyanilino)quinoline compound was prepared in an analogous fashion to Example 9 with the modification that 4-nitroaniline was used as the starting material instead of 6-aminoindazole and p-butoxyaniline was used in the displacement of the 4-chloro substituent instead of m-anisidine.

¹H NMR: δ 0.96 (t, 3H, J=6), 1.44 (m, 2H), 1.72 (m, 2H), 4.02 (t, 2H, J=6), 6.52 (d, 1H, J=7), 7.08 (d, 2H, J=8), 7.32 (d, 2H, J=8), 7.50 (d, 1H, J=9), 7.72 (s, 1H), 7.88 (d, 1H, J=8), 8.22 (br s, 1H).

M.S.: m/e 307 (M⁺, 100).

EXAMPLE 316-Amino-4-(3,4-difluoroanilino)-2-phenylquinoline hydrochloride

The title compound was prepared by a procedure similar to that described in Example 12.

¹H NMR: δ 6.98 (s, 1H), 7.4 - 7.8 (m, 8H), 7.90 (d, 2H, J=7), 8.20 (d, 1H, J=9).

M.S.: m/e 347 (M⁺, 100).

-32-

Analysis: Calc'd for $C_{21}H_{15}N_3F_2 \cdot 2HCl$: C, 60.01; H, 4.08; N, 10.00%. Found: C, 60.07; H, 4.21; N, 9.79%.

EXAMPLE 32

5 4-(p-Cyclohexylmethoxyanilino)-2-phenyl-6-ureidoquinoline hydrochloride

This compound was prepared from the corresponding 6-amino-4-(p-cyclohexylmethoxyanilino)-2-phenylquinoline with trichloroacetyl isocyanate in THF followed by cleavage of the trichloroacetyl group with methanol/sulfuric acid. The hydrochloride salt was formed by treatment with HCl in ether.

1H NMR: δ 1.0 - 1.3 (m, 5H), 1.6 - 1.9 (m, 6H), 3.80 (d, 1H, J=5), 6.28 (br s, 2H), 6.74 (s, 1H), 7.06 (d, 2H, J=8), 7.38 (d, 2H, J=8), 7.6 (m, 3H), 7.78 (m, 2H), 7.96 (d, 1H, J=9), 8.10 (d, 1H, J=9), 8.58 (s, 1H), 9.32 (s, 1H).

M.S.: m/e 466 (M^+ , 30).

High Resolution Mass Spectrum: Calc'd for $C_{29}H_{30}N_4O_2$: 466.2369. Found: 466.2396.

EXAMPLE 33

20 6-Acetamido-4-(p-cyclohexylmethoxyanilino)-2-phenylquinoline hydrochloride

This compound was prepared from the corresponding 6-amino-4-(p-cyclohexylmethoxyanilino)-2-phenylquinoline with acetic anhydride, DMAP, and triethylamine in methylene chloride, followed by treatment with HCl to form the hydrochloric salt.

1H NMR: δ 1.0 - 1.3 (m, 5H), 1.6 - 1.9 (m, 6H), 2.18 (s, 3H), 3.82 (d, 2H, J=6), 6.80 (s, 1H), 7.08 (d, 2H, J=9), 7.42 (d, 2H, J=9), 7.6 (m, 3H), 7.83 (d, 2H, J=7), 7.96 (d, 1H, J=9), 8.26 (d, 1H, J=9), 8.95 (s, 1H).

M.S.: m/e 465 (M^+ , 100).

High Resolution Mass Spectrum: Calc'd for $C_{30}H_{31}N_3O_2$: 465.2416. Found: 465.2434.

-33-

EXAMPLE 34N⁴-[4-(Cyclohexylmethoxy)phenyl]-2-methylquinolin-4,8-diamine Hydrochloride HemihydrateA. N-[4-(Cyclohexylmethoxy)phenyl]-2-methyl-8-nitroquinolin-4-amine Hydrochloride Hydrate

A solution of 1.0 g (4.5 mmol) of 4-chloro-2-methyl-8-nitroquinoline, 1.0 g (4.9 mmol) of 4-(cyclohexylmethoxy)-aniline and 30 mL of ethanol was heated under reflux for five hours. After cooling to room temperature, the reaction solution was evaporated to a residue which was slurried in diethyl ether and filtered to furnish 2.0 g (99%) of N-[4-(cyclohexylmethoxy)phenyl]-2-methyl-8-nitroquinolin-4-amine hydrochloride hydrate: m.p. 211-214°C (uncorr.).

Anal. Calcd for C₂₃H₂₅N₃O₃, HCl, H₂O (445.94): C, 61.94; H, 6.33; N, 9.43. Found: C, 62.24; H, 6.13; N, 9.14.

B. N⁴-[4-(Cyclohexylmethoxy)phenyl]-2-methylquinolin-4,8-diamine Hydrochloride Hemihydrate

Palladium-on-carbon (180 mg of 5% material) was added to a solution of 100 mL of ethanol and 1.8 g (4.0 mmol) of the nitroquinoline described immediately above. The mixture was then shaken in a Parr apparatus under three atmospheres of hydrogen for an hour. The mixture was filtered, and the filtrate was evaporated under reduced pressure to give 1.0 g (61%) of N⁴-[4-(cyclohexylmethoxy)phenyl]-2-methylquinolin-4,8-diamine hydrochloride hemihydrate: m.p. 274-277°C. A small portion was recrystallized from acetic acid for analysis; m.p. 280-284°C.

Anal. Calcd for C₂₃H₂₇N₃O, HCl, 0.5 H₂O (406.945): C, 67.88; H, 7.18; N, 10.33. Found: C, 67.91; H, 6.89; N, 10.21.

EXAMPLE 354-(4-Butylphenylamino)-2-methylquinolin-6-ol Hydrobromide Hydrate

A. N-(4-Butylphenyl)-6-methoxy-2-methylquinolin-4-amine. In a 100 mL three-neck round bottom flask under a nitrogen atmosphere and with magnetic stirring, a solution of 502 mg (2.42 mmol) of 4-chloro-6-methoxy-2-methyl-

-34-

quinoline, 450 mg (3.02 mmol) of 4-butyraniline and 25 mL of ethanol was heated under reflux for an hour. The reaction solution was evaporated under reduced pressure to furnish a residue which was then chromatographed on silica gel (eluant
5 9:1 chloroform-methanol) to give 511 mg of the desired product. The sample was recrystallized from ethanol-water to give 320 mg (41%) of pure N-(4-butylphenyl)-6-methoxy-2-methylquinolin-4-amine: m.p. 200-201°C.

Anal. Calcd for $C_{21}H_{24}N_2O$ (320.422): C, 78.82; H, 7.56;
10 N, 8.75. Found: C, 78.49; H, 7.45; N, 8.71.

B. 4-(4-Butylphenylamino)-2-methylquinolin-6-ol Hydrobromide Hydrate

Under a nitrogen atmosphere and with magnetic stirring, a solution of 17.5 mL of 48% hydrobromic acid and 142 mg
15 (0.442 mmol) of N-(4-butylphenyl)-6-methoxy-2-methylquinolin-4-amine was heated under reflux overnight. The reaction mixture was allowed to cool to room temperature whereupon a precipitate formed. The mixture was filtered and washed with ethyl acetate to afford 92 mg of solid
20 material. This was recrystallized from 2-propanol to give 55 mg (31%) of 4-(4-butylphenylamino)-2-methylquinolin-6-ol hydrobromide hydrate: m.p. 264-265°C.

Anal. Calcd for $C_{20}H_{22}N_2O \cdot HBr \cdot H_2O$ (405.324): C, 59.27; H, 6.22; Br, 19.71; N, 6.91. Found: C, 59.52; H, 6.31; Br,
25 19.32; N, 6.84.

EXAMPLE 36

4-(4-Chlorophenylamino)-2-methylquinolin-6-ol Hydrobromide Hydrate

A. N-(4-Chlorophenyl)-6-methoxy-2-methylquinolin-4-amine hydrochloride
30

In a manner similar to that described in Example 35, Part A, 4-chloro-6-methoxy-2-methylquinoline and 4-chloro-aniline were transformed into N-(4-chlorophenyl)-6-methoxy-2-methylquinolin-4-amine hydrochloride: m.p. 305-
35 307°C.

Anal. Calcd for $C_{17}H_{15}ClN_2O$, HCl (335.225): C, 60.90; H, 4.81; N, 8.36. Found: C, 60.92; H, 4.78; N, 8.33.

-35-

B. 4-(4-Chlorophenylamino)-2-methylquinolin-6-ol
Hydrobromide Hydrate

In a manner similar to that described in Example 35,
Part B, N-(4-chlorophenyl)-6-methoxy-2-methylquinolin-4-
5 amine hydrochloride was transformed into the title compound:
m.p. 308-310°C.

Anal. Calcd for $C_{16}H_{13}ClN_2O$, HBr, H_2O (383.665): C,
50.09; H, 4.20; N, 7.30. Found: C, 49.68; H, 4.09; N,
7.17.

10

EXAMPLE 37

4-(4-Chlorophenylamino)-2-phenylquinolin-6-ol
Hydrobromide Dihydrate

A. N-(4-chlorophenyl)-6-methoxy-2-phenylquinolin-4-
amine Hydrochloride Hydrate

15 In a manner similar to that described in Example 35,
part A, 4-chloro-6-methoxy-2-phenylquinoline and 4-
chloroaniline were transformed into 1.2 g (80%) of the title
compound: m.p. > 250°C.

Anal. Calcd for $C_{22}H_{17}ClN_2O$, HCl, H_2O (415.306): C,
20 63.62; H, 4.85; N, 6.75. Found: C, 63.68; H, 4.86; N,
6.77.

B. 4-(4-Chlorophenylamino)-2-phenylquinolin-6-ol
Hydrobromide Dihydrate

In a manner similar to that described in Example 35,
25 Part B, N-(4-chlorophenyl)-6-methoxy-2-phenylquinolin-4-
amine hydrochloride hydrate was transformed into the title
compound: m.p. 180-185°C (decomp.).

Anal. Calcd for $C_{21}H_{15}ClN_2O$, HBr, $2H_2O$ (463.747):
C, 54.39; H, 4.35; N, 6.04. Found: C, 54.14; H, 3.82; N,
30 5.91.

EXAMPLE 38

2-Methyl-4-octylaminoquinolin-6-ol Hydrobromide
Hemihydrate

In a 100 mL three-neck round bottom flask under a
35 nitrogen atmosphere and with magnetic stirring, a solution
of 1.0 g (4.8 mmol) of 4-chloro-6-methoxy-2-methylquinoline
and 10 mL of n-octylamine was heated under reflux for three

-36-

hours. Upon cooling to room temperature, the reaction mixture formed a glassy solid which was filtered. This was triturated under isopropyl ether filtered and washed with additional ether. The solid was stirred with a mixture of
5 water and ethyl acetate; insolubles were filtered and discarded; the ethyl acetate layer eventually furnished 500 mg of 6-methoxy-2-methyl-N-octylquinolin-4-amine hydrochloride: m.p. 178-179°C. Without further purification, a solution of 350 mg (1.04 mmol) of this
10 material and 42 mL of 48% hydrobromic acid was heated reflux for 18 hours. Upon cooling, the reaction solution gave a precipitate which was filtered. The filtrate was evaporated to furnish a solid residue. The combined solids were recrystallized from hot water to give 45 mg (12%) of 2-
15 methyl-4-octylaminoquinolin-6-ol hydrobromide hemihydrate: m.p. 176-178°C.

Anal. Calcd for $C_{18}H_{26}N_2O$, HBr, 0.5 H_2O (376.328): C, 57.44; H, 7.50; N, 7.45. Found: C, 57.23; H, 7.40; N, 7.23.

20

EXAMPLE 394-[4-(Cyclohexylmethoxy)phenylamino]-2-methylquinolin-6-ol Hydrochloride HydrateA. 4-Chloro-2-methylquinolin-6-ol

Under a nitrogen atmosphere in a 500 single-neck round
25 bottom flask equipped with a condenser and a magnetic stirrer, a solution of 2.00 g (9.62 mmol) of 4-chloro-6-methoxy-2-methylquinoline and 150 mL of 48% hydrobromic acid was heated under reflux for 90 minutes. Upon cooling to room temperature, the reaction solution was evaporated under
30 reduced pressure to afford a solid residue. The residue was slurried in chloroform filtered and washed with chloroform. The solid was next slurried in a mixture of saturated aqueous sodium carbonate and ethyl acetate for 15 minutes, filtered and washed successively with saturated aqueous
35 sodium carbonate, water and ethyl acetate. After air drying there was obtained 741 mg (40%) of 4-chloro-2-methylquinolin-6-ol: m.p. 233°C.

-37-

Anal. Calcd for $C_{10}H_8ClNO$ (193.627): C, 62.03; H, 4.16; N, 7.24. Found: C, 62.02; H, 4.07; N, 7.20.

B. 4-[4-(Cyclohexylmethoxy)phenylamino]-2-methylquinolin-6-ol Hydrochloride Hydrate

5 Under a nitrogen atmosphere in a 100 mL three-neck round bottom flask equipped with a magnetic stirrer and condenser, a solution of 580 mg (3.0 mmol) of 4-chloro-2-methylquinolin-6-ol, 707 mg (3.45 mmol) of 4-(cyclohexylmethoxy)aniline and 35 mL of ethanol was heated under
10 reflux for three hours. Upon cooling to room temperature a precipitate formed. This was filtered, washed with ethanol, and allowed to dry. There was obtained 1.0 g of a solid that was recrystallized from n-butanol to furnish 811 mg (65%) of the title compound as yellow crystals: m.p.
15 318-322°C (uncorr.).

Anal. Calcd for $C_{23}H_{26}N_2O_2$, HCl, H_2O (416.935): C, 66.25; H, 7.01; N, 6.72. Found: C, 66.18; H, 6.74; N, 6.75.

EXAMPLE 40

4-(3-Methoxyphenylamino)-2-methylquinolin-6-ol
20 Hydrochloride

In a manner similar to that described in Example 39, Part B, 4-chloro-2-methylquinolin-6-ol and m-anisidine were converted into the title compound: m.p. 309-311°C.

Anal. Calcd for $C_{17}H_{16}N_2O_2$, HCl (316.779): C, 64.45;
25 H, 5.41; N, 8.85. Found: C, 64.15; H, 5.54; N, 8.70.

EXAMPLE 41

4-Hexylamino-2-methylquinolin-6-ol Hydrochloride
Hemihemihydrate

In a manner similar to that described in Example 39,
30 Part B, 4-chloro-2-methylquinolin-6-ol and hexylamine were transformed into the title compound: m.p. 234-236°C.

Anal. Calcd for $C_{16}H_{22}N_2O$, HCl, 0.25 H_2O (299.321): C, 64.20; H, 7.91; N, 9.26. Found: C, 64.40; H, 7.94; N, 9.40.

-38-

EXAMPLE 424-Dodecylamino-2-methylquinolin-6-ol Hydrochloride Hydrate

In a manner similar to that described in Example 39,
5 Part B, 4-chloro-2-methylquinolin-6-ol and dodecylamine were transformed into the title compound: m.p. 198-203°C.

Anal. Calcd for $C_{22}H_{34}N_2O$, HCl, H_2O (396.989): C, 66.56; H, 9.39; N, 7.06. Found: C, 66.05; H, 9.41; N, 6.98.

EXAMPLE 4310 4-Dodecylamino-2-methylquinolin-6-ol Methanesulfonate

A stirred mixture of 1.2 g (3.0 mmol) of the hydrochloride salt described in Example 42, ethyl acetate and water was adjusted to pH 8 by the addition of aqueous 4 N sodium hydroxide. The organic phase was evaporated under
15 reduced pressure to afford 1.0 g (2.9 mmol) of the free base as a yellow solid. This was treated with an equivalent of methanesulfonic acid. The resulting solid was triturated with isopropyl ether and then recrystallized from acetonitrile to furnish 600 mg of the title product as
20 golden needles: m.p. 123-125°C.

Anal. Calcd for $C_{22}H_{34}N_2O$, CH_3SO_3H (438.62): C, 62.98; H, 8.73; N, 6.38. Found: C, 63.05; H, 8.73; N, 6.46.

EXAMPLE 444-Decylamino-2-methylquinolin-6-ol Methanesulfonate

25 In the manner similar to those described in Example 39, Part B, and Example 43, 4-chloro-2-methylquinolin-6-ol and decylamine (neat at 130°C) were transformed into the title compound: m.p. 100-102°C.

Anal. Calcd for $C_{20}H_{30}N_2O$, CH_3SO_3H (410.57): C, 61.43; H, 8.34; N, 6.82. Found: C, 61.36; H, 8.39; N, 6.73.

EXAMPLE 454-Tetradecyl-2-methylquinolin-6-ol Hydrochloride Hydrate

A solution of 150 mg (0.78 mmol) of 4-chloro-2-methyl-
35 quinolin-6-ol, 174 mg (0.81 mmol) of n-tetradecylamine, and 5 mL of n-butanol was heated under reflux for 24 hours. Excess butanol was removed by codistillation with

-39-

cyclohexane. The residue was chromatographed on 30 g of silica gel (eluent 1:9 methanol-dichloromethane) to furnish crude product. This was taken up in methanol, and the solution was treated with dry hydrogen chloride gas. The solution was evaporated under reduced pressure to give the title compound as crystalline material: m.p. 180-183°C.

Anal. Calcd for $C_{24}H_{38}N_2O$, HCl, H_2O (425.04): C, 67.82; H, 9.72; N, 6.59. Found: C, 67.73; H, 9.35; N, 6.64.

EXAMPLE 46

10 4-[(3-Methoxyphenyl)amino]quinolin-6-ol Mixed Hydrobromide and Hydrochloride Salts

A. 4-Chloroquinolin-6-ol Hydrobromide

 In a flame dried three-neck 50 mL round bottom flask equipped with a rubber septum and a mechanical stirrer, and under a nitrogen atmosphere at room temperature, 4.0 mL of 1.0 M boron tribromide in dichloromethane (Aldrich Chemical Co.) was added portionwise through gas tight syringe to a solution of 727 mg (3.75 mmol) of 4-chloro-8-methoxyquinoline and 5.0 mL of dichloromethane. A thick solid formed immediately and after 0.5 hour of stirring another 4.0 mL portion of boron tribromide solution was added and stirring was continued overnight. The reaction mixture was treated dropwise with methanol. The solution was evaporated under reduced pressure, and the residue titrated with dichloromethane and filtered to afford 844 mg (86%) of the title compound: m.p. 243-244°C.

 Anal. Calcd for C_9H_6ClNO , HBr (260.51): C, 41.49; H, 2.71; N, 5.38. Found: C, 41.46; H, 2.63; N, 5.27.

B. 4-[(3-Methoxyphenyl)amino]quinolin-6-ol Mixed 30 Hydrobromide and Hydrochloride Salts

 A solution of 245 mg (0.94 mmol) of 4-chloroquinolin-6-ol hydrobromide, 0.3 mL (2.72 mmol) of m-anisidine and 30 mL of ethanol was heated under reflux for an hour. The reaction solution was evaporated under reduced pressure to afford a solid residue which was then slurried first in diethyl ether and then in acetone. The solid was

-40-

recrystallized from hot acetone to give 200 mg (65%) of the title product: m.p. 241-243°C.

Anal. Calcd for $C_{16}H_{14}N_2O_2$, 0.6 HBr, 0.4 HCl (329.42): C, 58.33; H, 4.59; Br, 14.55; Cl, 4.30; N, 8.51. Found: C, 57.68; H, 4.52; Br, 14.17; Cl, 4.37; N, 8.30.

EXAMPLE 47

4-[(4-Cyclohexylmethyloxy)phenylamino]quinolin-6-ol Mixed Hydrobromide and Hydrochloride Salts

In a manner similar to that described in Example 46,
10 Part B, 4-chloroquinolin-6-ol hydrobromide and 4-(cyclohexylmethyloxy)aniline were transformed into 267 mg (67%) of the title compound: m.p. 235-238°C.

Anal. Calcd for $C_{22}H_{24}N_2O_2$, 0.9 HBr, 0.1 HCl (424.90): C, 62.18; H, 5.93; N, 6.59. Found: C, 62.23; H, 6.32;
15 N, 6.56.

EXAMPLE 48

4-(Cyclohexylamino)quinolin-6-ol Hydrobromide Hydrate

4-(Cyclohexylamino)quinolin-6-ol Hydrobromide Hydrate.

A solution of 245 mg (0.94 mmol) of 4-chloroquinolin-6-ol
20 hydrobromide and 1.0 mL of cyclohexylamine was heated under reflux overnight. Excess volatile components of the reaction mixture were evaporated under reduced pressure. The residue was slurried with isopropyl ether and then filtered. The solids were recrystallized from hot acetic
25 acid to afford 129 mg (40%) of the title compound: m.p. 280-285°C (dec.).

Anal. Calcd for $C_{15}H_{18}N_2O_2$, HBr, H₂O (341.24): C, 52.79; H, 6.20; N, 7.68. Found: C, 52.85; H, 6.33; N, 8.12.

EXAMPLE 49

30 4-(Dodecylamino)quinolin-6-ol Methanesulfonate

A. 4-Chloroquinolin-6-ol

A solution of 4.99 g (18.1 mmol) of 4-chloro-6-methoxyquinoline and 50 mL of 48% hydrobromic acid is heated under reflux for seven hours. Upon cooling to room
35 temperature, the reaction solution afforded a dark solid that was then slurried in water. The aqueous mixture was adjusted to pH 10 by the addition of 4 N sodium hydroxide.

-41-

The resulting solid was filtered, washed with water and air-dried to give 1.83 g (56%) of 4-chloroquinolin-6-ol: m.p. 223°C.

B. 4-(Dodecylamino)quinolin-6-ol Methanesulfonate

5 A mixture of 800 mg (4.4 mmol) of 4-chloroquinolin-6-ol and 4.12 g (22.2 mmol) of dodecylamine was heated at 130°C for nine hours. Upon cooling to room temperature the dark reaction mixture was slurried with isopropyl ether and then filtered. The solids were boiled with water, filtered, and
10 then air dried to give 441 mg (30%) of the waxy free base. A solution of the free base, 92 μ L of methanesulfonic acid, and methanol afforded 550 mg (29%) of the title compound as crystals: m.p. 148-149°C.

Anal. Calcd for $C_{21}H_{32}N_2O$, CH_3SO_3H (424.59): C, 62.23; H, 8.48; N, 6.59. Found: C, 62.23; H, 8.55; N, 6.63.

EXAMPLE 50

4-(Decylamino)quinolin-6-ol Hydrochloride

In a manner similar to that described in Example 49, Part B, 4-chloroquinolin-6-ol and decylamine were
20 transformed into the title compound as the hydrochloride salt: m.p. 197-199°C.

Anal. Calcd for $C_{19}H_{28}N_2O$, HCl, (336.89): C, 67.74; H, 8.67; N, 8.31. Found: C, 67.93; H, 8.92; N, 8.16.

EXAMPLE 51

25 4-(4-Butylphenylamino)-2-methylquinolin-7-ol Hydrobromide Hemihydrate

A. N-(4-Butylphenyl)-7-methoxy-2-methylquinolin-4-amine Hydrochloride

In a manner similar to that described in Example 35, Part A, 4-chloro-7-methoxy-2-methylquinoline and 4-butylaniline were transformed into the title compound: m.p. 245-246°C.

Anal. Calcd for $C_{21}H_{24}N_2O$, HCl (356.883): C, 70.67; H, 7.06; N, 7.85. Found: C, 70.51; H, 6.93; N, 7.81.

35

-42-

B. 4-(4-Butylphenylamino)-2-methylquinolin-7-ol Hydrobromide Hemihydrate

In a manner similar to that described in Example 35, Part B, N-(4-butylphenyl)-7-methoxy-2-methylquinolin-4-amine
5 Hydrochloride was transformed into the title compound: m.p. 328-330°C.

Anal. Calcd for $C_{20}H_{22}N_2O$, HBr, 0.5 H₂O (396.316):
C, 60.92; H, 6.10; N, 7.07. Found: C, 60.92; H, 5.63;
N, 7.04.

10

EXAMPLE 52

4-[4-(Cyclohexylmethyloxy)phenylamino]-2-methylquinolin-7-ol Mixed Hydrobromide and Hydrochloride Salts

A. 4-Chloro-2-methylquinolin-7-ol Hydrobromide

In a manner similar to that described in Example 46,
15 Part A, 4-chloro-7-methoxy-2-methylquinoline was transformed into the title product: m.p. > 300°C.

Anal. Calcd for $C_{10}H_8ClNO$, HBr (274.54): C, 43.75;
H, 3.30; N, 5.10. Found: C, 44.15; H, 3.21; N, 4.98.

B. 4-Chloro-2-methylquinolin-7-ol

20 A mixture of 2.33 g (8.49 mmol) of the hydrobromide salt described above, ethyl acetate and aqueous saturated sodium carbonate was stirred for an hour. The organic phase was then washed with aqueous saturated NaCl, dried over anhydrous magnesium sulfate, filtered, and evaporated to
25 furnish 1.6 g (100%) of 4-chloro-2-methylquinolin-7-ol.

C. 4-[4-(Cyclohexylmethyloxy)phenylamino]-2-methylquinolin-7-ol Mixed Hydrobromide and Hydrochloride Salts

In a manner similar to that described in Example 46,
30 Part B, 4-chloro-2-methylquinolin-7-ol hydrobromide and 4-(cyclohexylmethyloxy)aniline were transformed into the title compound: m.p. 330-333°C.

Anal. Calcd for $C_{23}H_{26}N_2O_2$, 0.5 HBr, 0.5 HCl (421.14):
C, 65.59; H, 6.46; N, 6.65. Found: C, 65.51; H, 6.26;
35 N, 6.55.

-43-

EXAMPLE 534-(Dodecylamino)-2-methylquinolin-7-ol Methanesulfonate

In a manner similar to that described in Example 49, Part B, 4-chloro-2-methylquinolin-7-ol and dodecylamine were transformed into the title compound: m.p. 186-187°C.

Anal. Calcd for $C_{22}H_{34}N_2O$, CH_3SO_3H (438.62): C, 62.98; H, 8.73; N, 6.38. Found: C, 62.90; H, 8.55; N, 6.34.

EXAMPLE 544-(Decylamino)-2-methylquinolin-7-ol Methanesulfonate

In a manner similar to that described in Example 49, Part B, 4-chloro-2-methylquinolin-7-ol and decylamine were transformed into the title compound: m.p. 188-189°C.

Anal. Calcd for $C_{20}H_{30}N_2O$, CH_3SO_3H (410.57): C, 61.43; H, 8.34; N, 6.82. Found: C, 61.53; H, 8.51; N, 6.75.

EXAMPLE 554-(4-Butylphenylamino)quinolin-8-ol Hydrochloride Hydrate

A. N-(4-Butylphenyl)-8-methoxyquinolin-4-amine Hydrochloride Hydrate

In a manner similar to that described in Example 35, Part A, 4-chloro-8-methoxyquinoline and 4-butyylaniline were transformed into the title compound: m.p. 132-134°C.

Anal. Calcd for $C_{20}H_{22}N_2O$, HCl , H_2O (360.87): C, 66.56; H, 6.98; N, 7.76. Found: C, 66.16; H, 6.85; N, 7.82.

B. 4-(4-Butylphenylamino)quinolin-8-ol Hydrochloride Hydrate

In a flame dried single-neck round bottom flask equipped with a Dean-Stark trap and a condenser, a solution of 1.0 g (2.9 mmol) of N-(4-butylphenyl)-8-methoxyquinolin-4-amine hydrochloride and 20 mL of toluene was treated with 1.9 g (14.5 mmol) of anhydrous aluminum chloride. This was heated under reflux for five hours, and then allowed to cool to room temperature. The reaction solution was treated dropwise with water until a sticky solid formed. Work-up of the mixture eventually afforded 709 mg of crude product. This was recrystallized from

-44-

water-formic acid to furnish 340 mg (34%) of the title compound: m.p. 269°C.

Anal. Calcd for $C_{19}H_{20}N_2O$, HCl, H_2O (346.847): C, 65.79; H, 6.68; N, 8.07. Found: C, 65.34; H, 6.29; N, 7.84.

5

EXAMPLE 564-[4-(Cyclohexylmethyloxy)phenylamino]quinolin-8-ol Hydrochloride HydrateA. 4-Chloroquinolin-8-ol Hydrobromide

In a manner similar to that described in Example 46, Part A, 4-chloro-8-methoxyquinoline was transformed into the title product: m.p. 232-233°C.

B. 4-Chloro-quinolin-8-ol

A solution of 1.3 g of the hydrobromide salt and 50 mL of water was adjusted to pH 9 by the addition of 4 N sodium hydroxide. The resulting precipitate was filtered, washed with water, and air-dried to give 790 mg (52%) of the title compound: m.p. 143-145°C.

C. 4-[4-(cyclohexylmethyloxy)phenylamino]quinolin-8-ol Hydrochloride Hydrate

In a manner similar to that described in Example 46, Part B, 4-chloro-quinolin-8-ol hydrobromide and 4-(cyclohexylmethyloxy)aniline were transformed into and the title product: m.p. 286-288°C (from methanol-acetonitrile).

Anal. Calcd for $C_{22}H_{24}N_2$, HCl, H_2O (402.89): C, 65.58; H, 6.75; N, 6.95. Found: C, 65.82; H, 6.19; N, 6.90.

EXAMPLE 574-(Dodecylamino)quinolin-8-ol Hydrochloride

In a manner similar to that described in Example 49, Part B, 4-chloroquinolin-8-ol and n-dodecylamine were transformed into the title compound: m.p. 189-190°C; m/e 328 (molecular ion); NMR spectrum consistent with assigned structure.

-45-

EXAMPLE 584-[4-(Cyclohexylmethyloxy)phenylamino]quinolin-6,8-diol
HydrochlorideA. 6,8-Dimethoxyquinolin-4-ol

5 In a three neck round-bottom flask equipped with a reflux condenser and a mechanical stirrer, a solution of 10.0 g (69.3 mmol) of 2,2-dimethyl-1,3-dioxan-4,6-dione (Meldrum's acid) and 46 mL (277 mmol) of triethyl orthoformate was treated with 11.1 g (72.7 mmol) of 2,4-

10 dimethoxyaniline. The mixture was heated at 85°C for two hours. Upon cooling to room temperature, the reaction mixture was diluted with isopropyl ether and filtered to furnish 18.7 g of 5-[(2,4-dimethoxyphenyl)aminomethylene]-2,2-dimethyl-1,3-dioxan-4,6-dione as a bright orange solid.

15 This solid was then added portionwise to 80 mL of a boiling solution of biphenyl and diphenyl ether/biphenyl, (Dowtherm, trademark). After the final addition heating was continued for just 5 minutes. After cooling to room temperature, the reaction mixture was stored in the refrigerator overnight,

20 and then stirred with isopropyl ether for an hour. The solids were filtered and washed with isopropyl ether to afford 11.8 g (83%) of 6,8-dimethoxyquinolin-4-ol: m.p. 221-224°C.

B. 4-Chloro-6,8-dimethoxyquinoline

25 A solution of 6.5 g (31.6 mmol) of 6,8-dimethoxyquinolin-4-ol, 29 mL (316 mmol) of phosphorous oxychloride and 2.6 mL of N,N-dimethylformamide was stirred at room temperature for seven hours. The reaction solution was poured into a stirred mixture of ice and water. The aqueous

30 mixture was washed three times with 300 mL portions of ethyl acetate, and then adjusted to pH 6 by the addition of solid sodium carbonate. 4-Chloro-6,8-dimethoxyquinoline was thus obtained as a colorless solid: yield 5.73 g (81%). The product was recrystallized from hot water for analysis:

35 m.p. 115-116°C.

Anal. Calcd for $C_{11}H_{10}ClNO_2$ (223.66): C, 59.07; H, 4.50; N, 6.26. Found: C, 58.98; H, 4.24; N, 6.18.

-46-

C. 4-Chloroquinolin-6,8-diol Hemihydrate

In a manner similar to that described in Example 46, Part A, 4-chloro-6,8-dimethoxyquinoline was transformed into 4-chloroquinolin-6,8-diol hemihydrate: m.p. 209-211°C.

5 Anal. Calcd for $C_9H_6ClNO_2$, 0.5 H₂O (204.61): C, 52.83; H, 3.44; N, 6.84. Found: C, 52.95; H, 2.90; N, 6.81.

D. 4-[4-(Cyclohexylmethyloxy)phenylamino]quinolin-6,8-diol Hydrochloride

In a manner similar to that described in Example 39, 10 Part B, 4-chloroquinolin-6,8-diol hemihydrate and 4-(cyclohexylmethyloxy)aniline were transformed into the title compound: m.p. 294°C (dec.).

Anal. Calcd for $C_{22}H_{24}N_2O_3$, HCl (400.89): C, 65.91; H, 6.25; N, 6.98. Found: C, 65.63; H, 6.02; N, 7.05.

15

EXAMPLE 594-[4-(Cyclohexylmethyloxy)phenylamino]quinolin-6-methanol MethanesulfonateA. Ethyl 4-Hydroxyquinoline-6-carboxylate

In a manner similar to that described in Example 58, 20 Part A., 10 g (69 mmol) of 2,2-dimethyl-1,3-dioxan-4,6-dione and 11.4 g (69 mmol) of ethyl 4-aminobenzoate were transformed into the title product: yield 10.86 g (72%); m.p. 233-234°C.

Anal. Calcd for $C_{12}H_{11}NO_3$ (217.22): C, 66.35; H, 5.10; 25 N, 6.45. Found: C, 66.04; H, 4.92; N, 6.39.

B. Ethyl 4-Chloroquinoline-6-carboxylate

In a manner similar to that described in Example 58, Part B., 7.34 g (33.7 mmol) of ethyl 4-hydroxyquinolin-6-carboxylate was transformed into the title compound: yield 30 4.9 g (62%); m.p. 84-85°C.

Anal. Calcd for $C_{12}H_{10}ClNO_2$ (235.66): C, 61.16; H, 4.27; N, 5.94. Found: C, 61.35; H, 4.28; N, 5.82.

C. Ethyl 4-[4-(cyclohexylmethyloxy)phenylamino]quinolin-6-carboxylate Hydrochloride

35 In a manner similar to that described in Example 39, Part B., 2.0 g (8.48 mmol) of ethyl 4-chloroquinolin-6-carboxylate and 1.74 g (8.48 mmol) of 4-(cyclohexyl-

-47-

methyloxy)aniline were transformed into the title compound: yield 3.41 g (92%); m.p. 251-253°C.

Anal. Calcd for $C_{25}H_{28}N_2O_3$, HCl (440.96): C, 68.09; H, 6.62; N, 6.35. Found: C, 68.00; H, 6.40; N, 6.07.


5 D. 4-[4-(Cyclohexylmethyloxy)phenylamino]quinolin-6-methanol Methanesulfonate

A suspension of 519 mg (1.18 mmol) of the compound described in Part C, above, in water was adjusted to pH 12 by the addition 4 N sodium hydroxide, and stirred for 30
10 minutes. The aqueous mixture was then extracted three times with 250 mL portions of dichloromethane. The combined extracts were washed with saturated aqueous sodium chloride, and dried over anhydrous sodium sulfate. The organic phase was filtered and evaporated under reduced pressure. The
15 residue was dried in a vacuum oven for 72 hours, and then slurried with magnetic stirring in 7 mL of dichloromethane. At room temperature, 1.5 mL of 1.0 M borane-methylsulfide in dichloromethane (Aldrich) was added to the slurry. The reaction mixture was then heated under reflux for four
20 hours, and then allowed to cool. Methanol was added dropwise to the reaction mixture, and stirring was continued for an hour. Volatile components were evaporated from the reaction mixture, and the residue was chromatographed on 50 g of silica gel (eluent: 5:95 methanol-dichloro-
25 methane) to furnish crude 4-[4-(cyclohexylmethyloxy)phenyl-amino]quinolin-6-methanol. An additional chromatography procedure gave 40 mg of pure free base. To a methanol solution of the free base was added 10 μ L of methanesulfonic acid. Removal of the methanol led to a yellow oil which was
30 then crystallized from 2-propanol and isopropyl ether to give the title compound: yield 15 mg (3%); m.p. 158-160°C; m/e 362; NMR (deuteriochloroform) showed a new peak at δ 4.69 ppm (s, 2H, CH_2OH), and no peaks indicating the presence of an ethoxy group.

-48-

CLAIMS

1. A compound of the formula



wherein R¹ is (C₃-C₁₈) alkyl or phenyl optionally substituted with from one to three substituents independently selected from (C₁-C₆) alkyl, (C₁-C₆) alkoxy, halo, cyano, (C₃-C₈) cycloalkyl-(C₁-C₆)alkoxy wherein the cycloalkyl moiety may be substituted with from one to three (C₁-C₆)alkyl groups; hydroxyl, benzyloxy, carboxyl, hydroxy-(C₁-C₆) alkyl, pyrrolidino, piperidino, morpholino and -CONHQCOOH wherein Q is (C₁-C₄) alkyl;


R² is hydrogen, (C₁-C₆) alkyl, (C₃-C₇) cycloalkyl, phenyl or phenyl-(C₁-C₆) alkyl, wherein the phenyl moieties of said phenyl and said phenyl-(C₁-C₆) alkyl may be optionally substituted with from one to three substituents independently selected from (C₁-C₆) alkyl, (C₁-C₆)-alkoxy, halo, cyano and benzyloxy;

each of R³ and R⁴ is hydrogen;

R⁵ is hydrogen, amino, hydroxyl, 5-pyrazolyl, guanidino, hydroxy-(C₁-C₆) alkyl, -NHC(=NR⁸)R⁹, -NHSO₂R¹¹, -NHCOR¹² or ureido;

or R⁴ and R⁵, together with the carbons to which they are attached, form a group of the formula

-49-



wherein the carbon of group A labelled with an asterisk (*) represents the point of attachment of R^4 to the quinoline nucleus and the carbon of group A adjacent to it represents the point of attachment of R^5 to the quinoline nucleus;

R^6 is hydrogen, hydroxyl, amino, guanidino, $-NHC(=NR^8)R^9$, $-NHCOR^{13}$, $-NHSO_2R^{13}$ or ureido;

R^7 is hydrogen, halo, hydroxyl, amino, $-NHC(=NR^8)R^9$, $-NHSO_2R^{14}$, $-NHCOR^{14}$, ureido or guanidino;

R^8 and R^9 are independently selected from hydrogen, phenyl and (C_1-C_6) alkyl;


R^{11} , R^{12} , R^{13} and R^{14} are independently selected from (C_1-C_6) alkyl and phenyl optionally substituted with halo, (C_1-C_6) alkyl or (C_1-C_6) alkoxy;

except for 6-amino-4-anilino-2-phenylquinoline hydrochloride, 6-amino-4-(m-anisidino)-2-phenylquinoline hydrochloride, 6-amino-4-cyclohexylamino-2-phenylquinoline hydrochloride, 6-amino-4-(m-anisidino)-2-methylquinoline methanesulfonate, 6-amino-4-(p-toluidino)-2-methylquinoline methanesulfonate, 9-(p-anisidino)-2-methyl-1H-pyrazolo[3,4-f]quinoline hydrochloride, 9-(cyclohexylamino)-1H-pyrazolo[3,4-f]quinoline methanesulfonate, 9-(cyclopentylamino)-1H-pyrazolo[3,4-f]quinoline methanesulfonate, 4-(phenylamino)-2-phenylquinolin-6-ol hydrobromide, 4-(butylamino)-2-phenylquinolin-6-ol hydrobromide, 4-[(3-methoxyphenyl)amino]-2-methylquinolin-7-ol hydrochloride, 4-[(4-chlorophenyl)amino]-2-methylquinolin-7-ol hydrobromide, 4-(cyclohexylamino)-2-methylquinolin-6-ol hydrochloride, 4-[(3-methoxyphenyl)amino]quinolin-6,8-diol hydrochloride, and 4-(cyclohexyl-

-50-

amino)quinolin-8-ol hydrochloride or a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1, wherein R^3 , R^6 and R^7 are hydrogen and R^4 and R^5 , together with the carbons to which they are attached, from a group of the formula



10

wherein the carbon of group A labelled with an asterisk (*) represents the point of attachment of R^4 to the quinoline nucleus and the carbon of group A adjacent to it represents the point of attachment of R^5 to the quinoline nucleus.

3. A compound according to claim 1 wherein R^3 , R^4 , R^6 and R^7 are hydrogen and R^5 is amino, $-NHSO_2R^{11}$, $-NHCOR^{12}$ or hydroxy.

4. A compound according to claim 1, wherein said compound is selected from the group consisting of:

- 9-(m-Anisidino)-7-methyl-1H-pyrazolo[3,4-f]quinoline;
- 9-(p-Cyclohexylmethoxyanilino)-7-methyl-1H-pyrazolo[3,4-f]quinoline;
- 9-(Cyclohexylamino)-7-methyl-1H-pyrazolo[3,4-f]quinoline hydrochloride;
- 9-(p-Cyclohexylmethoxyanilino)-1H-pyrazolo[3,4-f]quinoline;
- 6-Amino-4-(p-cyclohexylmethoxyanilino)-2-phenylquinoline;
- 6-Amino-4-(p-chloroanilino)-2-phenylquinoline;
- 4-(p-Cyclohexylmethoxyanilino)-6-methylsulfonamido-2-phenylquinoline;
- 4-Decylamino-2-methylquinolin-6-ol;
- 4-Tetradecyl-2-methylquinolin-6-ol;
- 4-(Dodecylamino)quinolin-6-ol.

5. A pharmaceutical composition comprising an amount of a compound according to claim 1 effective in stimulating

-51-


or enhancing the immune response of a vertebrate, and a pharmaceutically acceptable carrier.

6. A method of stimulating or enhancing the immune response of a vertebrate, comprising administering to said
5 vertebrate an immune response stimulating or enhancing amount of a compound according to claim 1.

7. A radiolabelled of a compound according to claim 1.

8. A radiolabelled compound corresponding to claim 8,
10 wherein said radiolabelled compound is a compound according to claim 1 wherein one or more of the hydrogen atoms is replaced with tritium or one or more of the carbon atoms is replaced with a carbon-14 isotope thereof.

9. A process for making a compound of the formula
15



25 wherein R¹ is (C₃-C₁₈) alkyl or phenyl optionally substituted with from one to three substituents independently selected from (C₁-C₆) alkyl, (C₁-C₆) alkoxy, halo, cyano, (C₃-C₈) cycloalkyl-(C₁-C₆)alkoxy wherein the cycloalkyl moiety may be substituted with from one to three (C₁-C₆)alkyl groups;
30 hydroxyl, benzyloxy, carboxyl, hydroxy-(C₁-C₆) alkyl, pyrrolidino, piperidino, morpholino and -CONHQCOOH wherein Q is (C₁-C₄) alkyl;

R² is hydrogen, (C₁-C₆) alkyl, (C₃-C₇) cycloalkyl, phenyl or phenyl-(C₁-C₆) alkyl, wherein the phenyl moieties of said
35 phenyl and said phenyl-(C₁-C₆) alkyl may be optionally substituted with from one to three substituents


-52-

independently selected from (C₁-C₆) alkyl, (C₁-C₆)-alkoxy, halo, cyano and benzyloxy;

each of R³ and R⁴ is hydrogen;

R⁵ is hydrogen, amino, hydroxyl, 5-pyrazolyl, guanidino,
5 hydroxy-(C₁-C₆) alkyl, -NHC(=NR⁸)R⁹, -NHSO₂R¹¹, -NHCOR¹² or ureido;

or R⁴ and R⁵, together with the carbons to which they are attached, form a group of the formula



15

wherein the carbon of group A labelled with an asterisk (*) represents the point of attachment of R⁴ to the quinoline nucleus and the carbon of group A adjacent to it represents the point of attachment of R⁵ to the quinoline nucleus;

20 R⁶ is hydrogen, hydroxyl, amino, guanidino, -NHC(=NR⁸)R⁹, -NHCOR¹³, -NHSO₂R¹³ or ureido;

R⁷ is hydrogen, halo, hydroxyl, amino, -NHC(=NR⁸)R⁹, -NHSO₂R¹⁴, -NHCOR¹⁴, ureido or guanidino;


R⁸ and R⁹ are independently selected from hydrogen,
25 phenyl and (C₁-C₆)alkyl;

R¹¹, R¹², R¹³ and R¹⁴ are independently selected from (C₁-C₆) alkyl and phenyl optionally substituted with halo, (C₁-C₆)alkyl or (C₁-C₆)alkoxy;

except for 6-amino-4-anilino-2-phenylquinoline
30 hydrochloride, 6-amino-4-(m-anisidino)-2-phenylquinoline hydrochloride, 6-amino-4-cyclohexylamino-2-phenylquinoline hydrochloride, 6-amino-4-(m-anisidino)-2-methylquinoline methanesulfonate, 6-amino-4-(p-toluidino)-2-methylquinoline methanesulfonate, 9-(p-anisidino)-2-methyl-1H-pyrazolo[3,4-
35 f]quinoline hydrochloride, 9-(cyclohexylamino)-1H-pyrazolo[3,4-f]quinoline methanesulfonate, 9-(cyclopentylamino)-1H-pyrazolo[3,4-f]quinoline methane-

-53-


sulfonate, 4-(phenylamino)-2-phenylquinolin-6-ol hydrobromide, 4-(butylamino)-2-phenylquinolin-6-ol hydrobromide, 4-[(3-methoxyphenyl)amino]-2-methylquinolin-7-ol hydrochloride, 4-[(4-chlorophenyl)amino]-2-methylquinolin-7-ol hydrobromide, 4-(cyclohexylamino)-2-methylquinolin-6-ol hydrochloride, 4-[(3-methoxyphenyl)-amino]quinolin-6,8-diol hydrochloride, and 4-(cyclohexylamino)quinolin-8-ol hydrochloride or a pharmaceutically acceptable salt thereof comprising reacting a compound of the formula V



V

wherein R^2 , R^3 , R^4 , R^5 , R^6 and R^7 are described as above with an amine of the formula H_2NR^1 wherein R^1 is defined as above.

10. A process according to claim 9 wherein R^3 , R^6 and R^7 are hydrogen and R^4 and R^5 , together with the carbons to which they are attached, from a group of the formula



A

wherein the carbon of group A labelled with an asterisk (*) represents the point of attachment of R^4 to the quinoline nucleus and the carbon of group A adjacent to it represents the point of attachment of R^5 to the quinoline nucleus.

11. A process according to claim 9 wherein R^3 , R^4 , R^6 and R^7 are hydrogen and R^5 is amino, $-NHSO_2R^{11}$, $-NHCOR^{12}$ or hydroxy.

-54-

12. A process according to claim 9 wherein the compound formed is:

- 9-(m-Anisidino)-7-methyl-1H-pyrazolo[3,4-f]quinoline;
- 9-(p-Cyclohexylmethoxyanilino)-7-methyl-1H-
5 pyrazolo[3,4-f]quinoline;
- 9-(Cyclohexylamino)-7-methyl-1H-pyrazolo[3,4-f]quinoline hydrochloride;
- 9-(p-Cyclohexylmethoxyanilino)-1H-pyrazolo[3,4-f]quinoline;
- 10 6-Amino-4-(p-cyclohexylmethoxyanilino)-2-phenylquinoline;
- 6-Amino-4-(p-chloroanilino)-2-phenylquinoline;
- 4-(p-Cyclohexylmethoxyanilino)-6-methylsulfonamido-2-phenylquinoline;
- 15 4-Decylamino-2-methylquinolin-6-ol;
- 4-Tetradecyl-2-methylquinolin-6-ol;
- 4-(Dodecylamino)quinolin-6-ol.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 92/05435

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all)⁶

According to International Patent Classification (IPC) or to both National Classification and IPC

Int.Cl.5

C 07 D 471/04

A 61 K 31/47

C 07 D 215/44

C 07 D 401/04

C 07 D 215/42

II. FIELDS SEARCHED

Minimum Documentation Searched⁷

Classification System

Classification Symbols

Int.Cl.5

C 07 D 471/00

C 07 D 215/00

C 07 D 401/00

Documentation Searched other than Minimum Documentation
to the Extent that such Documents are Included in the Fields Searched⁸III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹

Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
X,Y	FR,A,2321291 (SERDEX) 18 March 1977, see page 1, lines 22-25; examples 1,4,10,11,15,16 ---	1,5
Y	EP,A,0187705 (NORWICH EATON-PHARMACEUTICALS, INC.) 16 July 1986, see claims (cited in the application) ---	1,5
X,Y	Annales Pharmaceutiques Francaises, vol. 35, nos. 7-8, 1977, (Paris, FR), A. DESVIGNES et al.: "Recherche sur les aminoquinoléines. XVIII. Activité antibactérienne et antifongique in vitro d'alkylamino-4 quinoléines à longues chaînes", pages 239-247, see complete document --- -/-	1,5

¹⁰ Special categories of cited documents:^{"A"} document defining the general state of the art which is not considered to be of particular relevance^{"E"} earlier document but published on or after the international filing date^{"L"} document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)^{"O"} document referring to an oral disclosure, use, exhibition or other means^{"P"} document published prior to the international filing date but later than the priority date claimed^{"T"} later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention^{"X"} document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step^{"Y"} document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.^{"A"} document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search

30-09-1992

Date of Mailing of this International Search Report

11. 11. 92

International Searching Authority

EUROPEAN PATENT OFFICE

Signature of Authorized Officer


 Kathie Weinberg

III. DOCUMENTS CONSIDERED TO BE RELEVANT

(CONTINUED FROM THE SECOND SHEET)

Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
X,Y	European Journal of Medicinal Chemistry, no. 6, November-December 1976, (Paris, FR), S. RENAULT et al.: "Recherche sur les aminoquinoléines. XIV : alkylamino-4 quinoléines à longues chaînes à activité amoebicide potentielle", pages 547-554, see complete document ---	1,5
X,Y	European Journal of Medicinal Chemistry, no. 6, November-December 1976, (Paris, FR), S. RENAULT et al.: "Recherche sur les aminoquinoléines. XV : alkylamino-4 quinoléines et quinaldines à longues chaînes à activité amoebicide potentielle", pages 555-560, see complete document ---	1,5
X,Y	European Journal of Medicinal Chemistry, no. 6, November-December 1976, (Paris, FR), S. RENAULT et al.: "Recherche sur les aminoquinoléines. XVI : alkylamino-4 quinoléines et quinaldines à longues chaînes à activité amoebicide potentielle", pages 561-565, see complete document ---	1,5
X	US,A,3859291 (MORTON-NORWICH PRODUCTS, INC.) 7 January 1975, see claim ---	1
X	GB,A, 980394 (ALLEN & HANBURY LTD) 13 January 1965, see starting products of examples 4-9, 11-13 ---	1
X	FR,M, 5389 (ROUSSEL-UCLAF) 23 October 1967, see page 1 ---	1
X	FR,A,2047882 (ROUSSEL-UCLAF) 19 March 1971, see example 3A --- -/-	1

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 92/05435

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim 6 is directed to a method of treatment of
(diagnostic method practised on) the human/animal body the search has been
effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such
an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.**

US 9205435
SA 63270

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 27/10/92. The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
FR-A- 2321291	18-03-77	GB-A- 1496371 BE-A- 845271	30-12-77 18-02-77
EP-A- 0187705	16-07-86	CA-A- 1263378 JP-A- 61210085 US-A- 4716168	28-11-89 18-09-86 29-12-87
US-A- 3859291	07-01-75	AU-A- 6954474 FR-A, B 2246559 GB-A- 1417539 JP-A- 50063120	04-12-75 02-05-75 10-12-75 29-05-75
GB-A- 980394		None	
FR-M- 5389	18-09-67	None	
FR-A- 2047882	19-03-71	None	
EP-A- 0326330	02-08-89	AU-A- 2872889 JP-A- 1246263 US-A- 5145843	03-08-89 02-10-89 08-09-92

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☐ BLACK BORDERS

☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

☐ FADED TEXT OR DRAWING

☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING

☐ SKEWED/SLANTED IMAGES

☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS

☐ GRAY SCALE DOCUMENTS

☐ LINES OR MARKS ON ORIGINAL DOCUMENT

☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.